Pharmacological Blockade of the 20-HETE Receptor Lowers Blood Pressure and Alters Vascular Function in Mice with Vascular Smooth Muscle- Specific Overexpression of CYP4a12-20-HETE Synthase

Kevin Agostinucci

Follow this and additional works at: https://touroscholar.touro.edu/nymc_students_theses

Part of the Medicinal and Pharmaceutical Chemistry Commons

Recommended Citation
Pharmacological Blockade of the 20-HETE Receptor Lowers Blood Pressure and Alters Vascular Function in Mice with Vascular Smooth Muscle-Specific Overexpression of CYP4a12-20-HETE Synthase

Kevin James Agostinucci

A Doctoral Dissertation in the Program in Pharmacology Submitted to the Faculty of the Graduate School of Basic Medical Sciences in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy at New York Medical College

2021
Pharmacological Blockade of the 20-HETE Receptor Lowers Blood Pressure and Alters Vascular Function in Mice with Vascular Smooth Muscle-Specific Overexpression of CYP4a12-20-HETE Synthase

Kevin James Agostinucci
Acknowledgements

The journey for the completion of my PhD at New York Medical College would not have been possible without the support of my colleagues, friends and family. First, I would like to thank Dr. Michal L. Schwartzman for the opportunity to complete my thesis under her mentorship. Dr. Schwartzman not only supported me throughout my time in her laboratory, but also challenged me, inspired me and facilitated me to be the best scientist I can be. I can’t thank you enough for everything you have done for me. I would like to thank the members of my thesis committee: Drs. Victor Garcia, Sachin Gupte, Alberto Nasjiletti, and Michael Wolin. I appreciate all the guidance, input, and assistance with regards to the completion of my thesis. To the past and present members of Dr. Schwartzman’s lab: Ankit Gilani, Sakib Hossain, Jonathan Pascale, Bibiana Iglesias, Elizabeth Villegas, Catherine D’addario, and Ghezal Froogh. Thank you for all the support you gave me throughout my time working in the lab. You all had valuable input that helped me complete some of my most difficult experiments. To all my friends I made during my time at NYMC: Juan Azcona, Roxanna Nahvi, Hannah Mulhall, Elizabeth Newman, Christina D’arco and Corey Gayletts. Thank you for all your support and encouragement. I will cherish all the moments we had together supporting each other in the lab and all the fun times we had at Captain Lawrence. To my parents, Karen and James and my sisters, Julie and Kristen, thank you for all your support throughout my academic career. You all have been there to give me the encouragement I need to help me push through the most difficult times. I love you all very much.
Table of Contents

Title page.......................................................................................................................i

Approval page ...............................................................................................................ii

Acknowledements ......................................................................................................iii

Table of contents ...........................................................................................................iv

List of figures ..................................................................................................................viii

List of Abbreviations ......................................................................................................xi

Abstract ..........................................................................................................................xii

Introduction and Background .......................................................................................1

Biosynthesis of 20-HETE ..............................................................................................1

20-HETE effects on the vasculature .............................................................................3

Actions on vascular endothelium .................................................................................3

Actions on the vascular smooth muscle .................................................................5

Other actions of 20-HETE............................................................................................8

The 20-HETE receptor, GPR75 ....................................................................................9

20-HETE and hypertension .........................................................................................12
Hypothesis ........................................................................................................... 16

Specific Aims ........................................................................................................ 17

Materials and Methods ...................................................................................... 19

Animals .................................................................................................................. 19

Blood Pressure Measurements .......................................................................... 19

Wired Myography ................................................................................................ 20

Pressure Myography ............................................................................................ 21

Sodium Excretion Studies ................................................................................... 22

Western Blot .......................................................................................................... 23

Reverse Transcription Polymerase Chain Reaction ........................................ 25

20-HETE Measurements .................................................................................... 26

Statistics ................................................................................................................ 27

Results ..................................................................................................................... 29

Aim 1: To determine if smooth muscle-specific overexpression of Cyp4a12-
20-HETE synthase causes hypertension and vascular dysfunction.............. 29
Myh11-Cre\(^{+/+}\)-Cyp4a12-Flox\(^{+/wt}\) (Myh11-4a12) had significantly elevated Cyp4a12 levels in vessels that resulted in elevated 20-HETE

Myh11-4a12 mice are hypertensive and have impaired vascular function

Markers of smooth muscle cell contraction and NO signaling were altered in Myh11-4a12 mice.

Aim 2: To determine if the vascular pathology in Myh11-4a12 mice is 20-HETE-dependent

Administration of AAA decreased systolic blood pressure and improves vascular function in mice with smooth muscle specific Cyp4a12 overexpression.

AAA administration improved media:lumen ratio but did not affect media thickness or cross-sectional area of RIA.

Markers of VSMC differentiation was elevated in Myh11-4a12 mice.

No differences in collagen synthesis was observed between Myh11-4a12 and wild type mice.

Aim 3: To explore cellular mechanisms underlying the increased contractility of arteries from mice with smooth muscle-specific overexpression of Cyp4a12
No changes were observed in ACE RNA expression between wild type and *Myh11-4a12* mice.

*Myh11-4a12* mice had reductions in eNOS activation which was increased with AAA treatment.

Administration of the 20-HETE receptor antagonist was able to reduce phosphorylation of myosin light chain.

20-HETE was able to increase Rho-kinase activity which was attenuated with AAA.

Discussion

Perspective and Significance

Reference:
List of Figures

Figure 1: Myh11-4a12 mice display overexpression of Cyp4a12 in vessels....... 32

Figure 2: Myh11-4a12 mice have elevated Cyp4a protein in vessels ............... 33

Figure 3: Myh11-4a12 mice display elevated 20-HETE.................................... 34

Figure 4: Mice with smooth muscle-specific overexpression of Cyp4a12 are hypertensive. ........................................................................................................... 35

Figure 5: Mice with smooth muscle-specific overexpression of Cyp4a12 have impaired relaxation ........................................................................................................... 36

Figure 6: Renal interlobar artery measurements of vascular remodeling are elevated in Myh11-4a12 mice ........................................................................................................... 37

Figure 7: Baseline expression of myosin light chain phosphorylation at serine 19 in mesenteric arteries were elevated in Myh11-4a12 mice........................................ 38

Figure 8: Baseline expression of phosphorylated and total eNOS was reduced in aortas of Myh11-4a12 mice........................................................................................................... 39

Figure 9: Administration of a 20-HETE receptor antagonist (AAA) was able to lower blood pressure after 12 days..................................................................................... 45

Figure 10: Plasma 20-HETE levels were unchanged after 12-day AAA treatment ................................................................................................................................. 46

Figure 11: Urine volume and sodium excretion in WT and Myh11-4a12 mice treated with and without AAA............................................................................................... 47
Figure 12: Vascular activity was improved after 12 days of AAA treatment.

Figure 13: *Myh11-4a12* mice had improved relaxation with AAA treatment *ex vivo*.

Figure 14: *Myh11-4a12* mice have an elevated media:lumen ratio that was reduced with AAA treatment, however, AAA did not reduce the thickness of the vessel.

Figure 15: Increases in markers of VSMC differentiation were observed in RIA of *Myh11-4a12* mice.

Figure 16: No differences in collagen expression were observed between *Myh11-4a12* and wild type mice.

Figure 17: No differences in ACE expression were observed between *Myh11-4a12* and wild type mice in mesenteric arteries.

Figure 18: Western blot analysis of eNOS and VASP phosphorylation in aorta.

Figure 19: Phosphorylation of eNOS at serine 1177 after 12 days of AAA treatment was reduced in mesenteric arteries of *Myh11-4a12* mice.

Figure 20: *Myh11-4a12* mice have elevated phosphorylation of myosin light chain that was reduced with 12 day AAA treatment.

Figure 21: ROCK1 protein expression was elevated in *Myh11-4a12* mice.
Figure 22: Addition of AAA or Y-27632 prevented 20-HETE-mediated increase in myogenic tone of RIA from WT mice ................................................................. 63

Figure 23: Absolute internal diameter (ID) and percent myogenic tone values of WT RIA at 80mmHg and 100mmHg ................................................................. 64
# List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20-HETE</td>
<td>20-hydroxy-5,8,11,14-eicosatetraenoic acid</td>
</tr>
<tr>
<td>AAA</td>
<td>N-disodium succinate-20-hydroxyeicosa-6(Z),15(Z)-diencarboxamide</td>
</tr>
<tr>
<td>CYP</td>
<td>Cytochrome P450</td>
</tr>
<tr>
<td>VSMC</td>
<td>Vascular Smooth Muscle Cell</td>
</tr>
<tr>
<td>EC</td>
<td>Endothelial Cell</td>
</tr>
<tr>
<td>GPR75</td>
<td>G-protein couple receptor 75</td>
</tr>
<tr>
<td>SBP</td>
<td>Systolic blood pressure</td>
</tr>
<tr>
<td>NO</td>
<td>Nitric Oxide</td>
</tr>
<tr>
<td>SNP</td>
<td>Sodium Nitroprusside</td>
</tr>
<tr>
<td>ID/OD</td>
<td>Inner diameter/outer diameter</td>
</tr>
<tr>
<td>Myh11</td>
<td>Smooth muscle myosin heavy chain 11</td>
</tr>
<tr>
<td>eNOS</td>
<td>Endothelial specific nitric oxide synthase</td>
</tr>
<tr>
<td>MLC</td>
<td>Myosin light chain</td>
</tr>
<tr>
<td>Tagln</td>
<td>Transgelin/Sm22α</td>
</tr>
<tr>
<td>Acta2</td>
<td>Smooth muscle actin 2</td>
</tr>
<tr>
<td>ROCK</td>
<td>Rho-kinase</td>
</tr>
<tr>
<td>ACE</td>
<td>Angiotensin converting enzyme</td>
</tr>
<tr>
<td>VASP</td>
<td>Vasodilator-stimulated phosphoprotein</td>
</tr>
<tr>
<td>RIA</td>
<td>Renal interlobar arteries</td>
</tr>
<tr>
<td>CSA</td>
<td>Cross-sectional area</td>
</tr>
</tbody>
</table>
Abstract

20-hydroxyeicosatetraenoic acid (20-HETE) is the ω-hydroxylation product of arachidonic acid catalyzed by CYP4A and 4F enzymes. 20-HETE is a vasoactive eicosanoid of the microcirculation exhibiting effects on both vascular smooth muscle cells (VSMC) and endothelial cells (EC). In VSMCs, 20-HETE's bioactions include the stimulation of contraction, migration, and growth. In ECs, elevated 20-HETE is associated with reduced nitric oxide (NO) bioavailability, increased angiotensin converting enzyme (ACE) expression, and the promotion of inflammation. Recently in our laboratory, we identified GPR75 as a novel target of 20-HETE that promotes changes in blood pressure and vascular function. The aim of this study is to assess the consequences of VSMC-targeted overexpression of Cyp4a12, the primary 20-HETE producing enzyme in mice, on blood pressure, vascular function, and vascular remodeling. Moreover, we looked to examine whether the administration of a 20-HETE receptor antagonist reverses the vascular phenotype associated with elevations in 20-HETE.

Mice with VSMC-specific overexpression of Cyp4a12 (Myh11-4a12) and their littermate controls (WT) were generated by crossbreeding Cyp4a12-flox mice (gifted by Dr. Schunck) with Myh11-Cre mice. Myh11-4a12 were administered AAA (10 mg.kg⁻¹.day⁻¹), a 20-HETE receptor antagonist, in the drinking water (vehicle). At the end of the experiments (12 days), renal interlobar arteries (RIA) and mesenteric arteries (MA) were harvested for the assessment of 20-HETE levels by LC-MS/MS, and vascular contractility, vasodilation, and remodeling using wire and pressure myography.
The *Myh11-4a12* mice showed higher Cyp4a levels in MA compared to WT mice (6.5±0.71 vs 3.4±0.70; Cyp4a/β-actin p<0.05). *Myh11-4a12* mice had increased 20-HETE levels in the MA (3334±891 vs. 545±197 pg/mg protein; p<0.05) and RIA (1859±376 vs 242±62 pg/mg protein; p<0.05), but, urine 20-HETE levels were not different (117±9 vs. 93±2 pg/mL; p=0.18) when compared to WT. *Myh11-4a12* mice displayed higher SBP compared to WT mice (145±2 vs. 127±2 mmHg; p<0.05). Administration of AAA for 12 days normalized BP in *Myh11-4a12* mice (124±2 mmHg vs. 147±4 mmHg, p<0.01). RIA from vehicle treated *Myh11-4a12* mice displayed a higher media to lumen (M:L) ratio (0.277±0.025 vs 0.163 ± 0.009; p<0.01) and cross sectional area (CSA) (15114±1871 vs 10560±641 μm²; p<0.01) compared to WT mice on vehicle. Moreover, RIA from *Myh11-4a12* mice on AAA exhibit a lower M:L ratio compared to *Myh11-4a12* mice on vehicle (0.215 ± 0.013, p<0.05), but CSA was not different (14268 ± 1259 μm²). Higher constrictor responsiveness to phenylephrine (EC$_{50}$: 1.63x10$^{-7}$ ± 3.75x10$^{-8}$ vs 5.00x10$^{-7}$ ± 0.7.85x10$^{-8}$ M, p<0.0001) and an impaired relaxation response to acetylcholine (Maximum response at 10$^{-4}$ M: 65 ± 1 vs 83 ± 2 % relaxation, p<0.001) was observed in RIA from *Myh11-4a12* mice compared to WT. Treatment of *Myh11-4a12* mice with AAA diminished the constrictor responsiveness to phenylephrine (EC$_{50}$ of 4.22x10$^{-7}$± 4.55x10$^{-8}$ M, p<0.0001) and improved the relaxation in response to acetylcholine (92 ± 2 % relaxation, p<0.001). *Myh11-4a12* mice had elevated phosphorylation of myosin light chain compared to WT mice (1.60 ± 0.23 vs 1.00 ± 0.06, Ser19 p-MLC/total MLC fold change, p<0.05). *Myh11-4a12* mice on AAA
exhibited a decrease in myosin light chain phosphorylation compared to Myh11-4a12 mice on vehicle (0.94 ± 0.11, Ser19 p-MLC/total MLC fold change, p<0.05). Upstream of myosin light chain is Rho kinase (ROCK). Expression of ROCK1 was assessed in RIA and Myh11-4a12 mice had increased ROCK1 expression compared to WT mice (1.60 ± 0.21 vs 1.00 ± 0.18, ROCK1/β-tubulin fold change, p<0.05) but AAA was unable to significantly reduce the expression (1.48 ± 0.20, ROCK1/β-tubulin fold change). Pressure myography was performed to assess 20-HETE receptor antagonism on ROCK activity. In RIA from WT mice, 20-HETE administration promoted a greater myogenic response and both AAA and ROCK inhibitor (Y-27632) inhibited the 20-HETE response in relation to the myogenic tone.

The results of this study suggest that VSMC specific overproduction of Cyp4a12 and 20-HETE promotes increase in blood pressure and changes in vascular reactivity. 20-HETE receptor antagonism was capable of reversing the vascular pathology in mice with elevated 20-HETE presumably through inhibition of ROCK activity.
Introduction and Background

Biosynthesis 20-HETE

20-HETE is the \(\omega\)-hydroxylation product of arachidonic acid catalyzed by cytochrome P450 enzymes (CYP4A/4F), with Cyp4a12 being the primary 20-HETE synthetase in mice. 20-HETE can be measured in tissue and in biological fluids. The vascular system is a primary site of 20-HETE production and it can be found in conduit arteries such as the aorta (Costa et al., 2018; Soler et al., 2018), and resistant arteries such as mesenteric arteries (Zhang et al., 2001), renal microvessels (Croft et al., 2000) and cerebral microvessels (Gebremedhin et al., 1998, 2000). Within each vessel type, 20-HETE is generated in the vascular smooth muscle cells (VSMC) (Harder et al., 1994; Gebremedhin et al., 1998) and endothelial cells (EC) (Zhu et al., 2002; Chen et al., 2016; Joseph et al., 2017). Circulating cells, such as endothelial progenitor cells, platelets, and myeloid cells, can also generate 20-HETE (Rosolowsky et al., 1996; Christmas et al., 2001; Wang et al., 2006; Tsai et al., 2011; Chen et al., 2014). The kidney tubules is another site of 20-HETE production where it can be measured within the tissue and contribute to the amount present in the urine (Gilani et al., 2020). Proximal tubules are the predominate sources of 20-HETE in the kidney tubules, with some production occurring in the thick ascending loop of henle (TALH), distal convoluted tubule and the collecting tubules (Carroll, M. A., Sala, A., Dunn, C.E., McGiff, J.C., 1991; Omata et al., 1992). Heart, brain, lung and adipose tissue are more examples of tissues that can produce 20-HETE (Zhu et al., 2002; Chuang et al., 2004; Joseph et al., 2017; Gilani et al., 2018, 2021).
Several factors can play a role in either the increase or decrease production of 20-HETE. Androgens are well known for inducing Cyp4a expression and their administration has been established as a model for global overexpression of 20-HETE in mice and rats (Holla et al., 2001; CC Wu et al., 2013). PPARγ agonists, such as Clofibrate, and parathyroid hormone can increase Cyp4 activity (Roman et al., 1993; Ribeiro et al., 1994; Silverstein et al., 1998). Angiotensin II, norepinephrine and endothelin-1 all facilitate increase in 20-HETE by promoting increases in intracellular calcium which is necessary for cytosolic phospholipase A2 activity and arachidonic acid release from phospholipids (Muthalif et al., 1996; Hercule and Oyekan, 2000; Parmentier et al., 2001; Tsai et al., 2011). Factors such as carbon monoxide or nitric oxide (NO) decrease 20-HETE production by binding to the heme moiety of Cyp4a enzyme to prevent its formation (Wang et al., 2003; Kaide et al., 2004).

Several cytochrome P450 enzymes have been shown to be involved in the production of 20-HETE across rodents and humans. In mice, Cyp4a10, Cyp4a12, and Cyp4a14 have some capacity to produce 20-HETE, with Cyp4a12 having the greatest capacity (Capdevila and Falck, 2000; Roman, 2002; Muller et al., 2007). The 20-HETE-producing enzymes in rats include Cyp4a1, Cyp4a2 and Cyp4a3 (Nguyen et al., 1999; Hardwick, 2008). The main 20-HETE-producing enzymes in humans are CYP4A11 and CYP4F2 (Powell et al., 1998; Lasker et al., 2000).
20-HETE effects on the vasculature

As indicated above, the vasculature is a significant source of 20-HETE production and a prime target of its actions. 20-HETE is a vasoactive lipid mediator affecting vascular tone and inflammation through actions on the vascular endothelium and the smooth muscle.

Actions on vascular endothelium

The vascular endothelium is a single layer of cells containing many factors that can diffuse to the smooth muscle to allow for changes in tension of vessels. 20-HETE overproduction has been shown to act in the endothelium to promote constriction. These actions include: 1) reduced NO bioavailability, 2) actions on renin-angiotensin-system, and 3) activation of endothelium inflammation processes.

NO is produced in the endothelium, by endothelial-specific nitric oxide synthase (eNOS), which is expelled to the VSMCs to exert its effect. 20-HETE can act on different parts of this signaling pathway to lower NO bioavailability. 20-HETE has a direct inhibitory effect on eNOS. Both in vitro and in vivo, 20-HETE has been shown to inhibit activation of eNOS by preventing phosphorylation at serine 1179 (Cheng et al., 2008; Inoue et al., 2009). Furthermore, 20-HETE has been shown to cause eNOS uncoupling with HSP90 via NF-κB-IKK signaling pathway (Cheng et al., 2010). 20-HETE also has indirect mechanisms which lower the bioavailability of NO. 20-HETE has been shown to increase superoxide production through NADPH oxidase-dependent and -independent mechanisms.
(Guo et al., 2007; Medhora et al., 2008). The increase in superoxide shunts NO to produce peroxynitrite which prevents it from migrating to the VSMCs to cause dilation (Medhora et al., 2008).

20-HETE has been shown to increase the expression and activity of angiotensin converting enzyme (ACE). Induction of 20-HETE production in vivo and in vitro has been shown to increase endothelial ACE expression via NF-κB-IKK pathway (Cheng et al., 2012; Garcia et al., 2016). Increases in ACE expression were accompanied by increases in angiotensin II levels which can act on its own receptor to cause changes in vessel function (Sodhi et al., 2010).

Vascular inflammation is another effect of 20-HETE in the endothelium. Reports have shown that 20-HETE can increase inflammatory markers such as IL-6 and IL-8 and adhesion molecules such as ICAM (Guo et al., 2007; Ishizuka et al., 2008). 20-HETE has been shown to increase NF-κB and MAPK, which facilitate the production of inflammatory markers (Guo et al., 2007; Ishizuka et al., 2008). The inflammatory state of the vessels can be reversed with administration of 20-HETE synthase inhibitor.

Angiogenesis is the process of making new blood vessels from preexisting vessels. This process requires the coordinated action of the endothelium to branch out from the vessel, migrate away from the branch point and form a tube structure. 20-HETE in vitro has been shown to increase EC proliferation as a result of both increases in VEGF and HIF-1α (Guo et al., 2007, 2009). These actions relied on an increased oxidative environment which resulted in the activation of the NF-κB pathway. Furthermore, 20-HETE in vivo has been shown
to upregulate angiogenesis by promoting endothelial progenitor cell homing and adhesion to the EC (Chen et al., 2014, 2016).

**Actions on vascular smooth muscle**

The VSMC is the contractile unit within the vasculature. It is located in the tunica media adjacent to ECs. Contraction caused by VSMCs play a role in maintaining blood flow to tissues. 20-HETE has been documented to change the VSMC phenotype by either: 1) increased sensitivity to contractile stimuli and 2) increased vessel wall thickness. These changes in VSMC physiology ultimately reduces blood flow, reduce compliance and increases in blood pressure.

VSMCs are responsible for causing contraction to redirect blood flow to tissue with higher metabolic demand. It is important for VSMC to be sensitive to specific stimuli that can promote changes in lumen diameter so tissues can receive a consistent blood flow. Autoregulation is an intrinsic property of a vessel where blood flow is maintained despite changes in pressure in the system. Autoregulation relies on the ability of the vessel to contract when it senses increase transluminal pressure, defined as the myogenic response (Davis et al., 1992). 20-HETE has been documented, in cerebral and renal circulation, to promote contraction which shift the autoregulation curve to the right so vessels maintain a constant flow at higher pressures (Zou et al., 1994; Gebremedhin et al., 2000). Inhibition of 20-HETE synthesis has been shown to cause dilation and prevent the vessel’s autoregulatory ability.
20-HETE has been shown to promote contraction in VSMCs by 1) increasing intracellular calcium and 2) activating Rho kinase. Calcium signaling is important because it is the initial step to cause VSMCs contraction. Calcium enters the VSMC through the L-type calcium channel which increases intracellular calcium levels. The increase in intracellular calcium activates calmodulin which then activates myosin light chain kinase (Tansey et al., 1994; Raina et al., 2009). Myosin light chain kinase phosphorylates the myosin light chain which is the necessary signal in order to initiate excitation-contraction in the VSMCs (Driska et al., 1981). The mechanisms by which 20-HETE affects intracellular calcium levels are through inhibition of the large-conductance Ca\(^{2+}\)-activated K\(^{+}\)-channel (BK\(_{Ca}^{2+}\)) (Zou et al., 1996; Lauterbach et al., 2002; Fan et al., 2013; Toth et al., 2013) and activation of L-type calcium channels (Gebremedhin et al., 1998).

Mechanisms exist within the VSMC to terminate signaling for contraction. Myosin light chain phosphatase is the protein within the VSMC that can remove the phosphate group off of myosin light chain and inhibit contraction (Wang et al., 2009). The activity of myosin phosphatase is regulated by Rho-kinase (ROCK). The activation of ROCK is initiated by GPCR-mediated mechanisms to activate Rho-GTP which removes the inhibitory subunit on ROCK (Swärd et al., 2003). 20-HETE has been reported to increase the activity of ROCK and increase myosin light chain phosphorylation (Randriamboavonjy et al., 2003). The inhibition of mechanisms to remove phosphate from myosin light chain sensitizes VSMCs to other constrictor stimuli.
The vascular wall is dynamic in that it can respond to external cues to change its architecture. In the normal state, the vessel is quiescent, but in the presence of certain stimuli, the vessel can undergo processes which allow it to thicken to compensate for the elevated pressure (Li et al., 1994; Garcia, et al., (2015b)). The consequences of remodeling in the vessels include decreases in compliance, reduced blood flow and ultimately even further increase in blood pressure. 20-HETE promotes changes in vascular wall remodeling without contribution to sympathetic nerve activation (Ding et al., 2013), as well as increase in ACE (Garcia, et al., (2015b)). Thus, 20-HETE displays its own signaling mechanism to promote thickening of the vascular wall. There are several signaling mechanisms which contribute to the mitogenic effect of 20-HETE. First, 20-HETE causes VSMC migration by activation of the MAP-kinase and PI3K/Akt signaling pathways (D Stec et al., 2007). Proliferation is also increased with 20-HETE. In vitro experiments with norepinephrine stimulation suggests that 20-HETE promotes proliferation via MAP-kinase signaling (Uddin et al., 1998; Kalyankrishna and Malik, 2003). 20-HETE has also been shown to cause proliferation in vivo. In an experiment by Orozco and colleagues (2013), they used a balloon injury model to promote carotid artery thickening which was prevented by administration of Cyp4a inhibitors (Orozco et al., 2013).

Another contributor to the changes in vascular wall remodeling is through changes in the architecture of the extracellular matrix (ECM). The ECM is comprised of structural proteins that give the vessels its ability to withstand changes in wall tension. The actions of 20-HETE within the ECM includes
increased collagen IV deposition (Ding et al., 2013) and elastin degradation (Soler et al., 2018). 20-HETE can increase reactive oxygen species in VSMCs (Lakhkar et al., 2016) which can act as a second messenger for the increased production of MMP12 that degrades elastin in conduit arteries (Soler et al., 2018). These actions contribute to the reduction in compliances that result in elevated blood pressure.

Other actions of 20-HETE

The actions of 20-HETE are not limited to maintenance of vascular tone within the central circulation. 20-HETE has numerous actions within structures of the kidney that result in changes in plasma osmolality. In renal preglomerular vessels, 20-HETE has been shown to sensitize vessels to phenylephrine-induced constriction and impaired relaxation after acetylcholine administration (CC Wu et al., 2013). Impairment in preglomerular microvessel activity resulted in reductions in glomerular filtration rate (Pandey et al., 2017) and an increase in proteinuria (Inoue et al., 2009). These changes resulted in an elevation in plasma osmolality and, ultimately, increases in blood volume. 20-HETE is produced and has actions within the kidney tubules (Omata et al., 1992; Lin et al., 1995). 20-HETE has been shown to act on different transporters in the nephron and, depending on the transporter, has a different effect on salt excretion. 20-HETE pro-natriuretic effect includes inhibition of Na⁺-K⁺-ATPase (Schwartzman et al., 1985; Nowicki et al., 1997) in the proximal tubule and sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb (Amlal et al., 1996, 1998). Furthermore, 20-
HETE also can increase the activity of the sodium chloride transporter resulting in an anti-natriuretic effect (Savas et al., 2016; Gilani et al., 2020).

20-HETE also has actions to promote increases in body weight gain and changes in insulin signaling. In human subjects, correlations have been shown between elevated 20-HETE in the urine and increased BMI. Mouse models of Cyp4a12 overexpression have also shown that elevated 20-HETE promotes increases in body weight and insulin resistance when on a high-fat diet (Gilani et al., 2018, 2021). These actions of global expression of Cyp4a12 were reversed when mice were administered 20-SOLA (a 20-HETE antagonist) (Gilani et al., 2018, 2021). The consequence of 20-HETE overproduction after a high-fat diet shows changes in insulin signaling and hyperglycemia. One report shows that overexpression of CYP4F2 promotes hyperglycemia on a normal diet (Lai et al., 2012). Hyperglycemia can be contributed to changes in insulin signaling. Reports have shown that 20-HETE can affect activation of the insulin receptor and/or the ability of IRS-1 to dock on the insulin receptor (Li et al., 2014; Gilani et al., 2018, 2021). One report shows that 20-HETE can inhibit glucose-mediated insulin secretion through the FFAR1 receptor (Tunaru et al., 2018).

The 20-HETE receptor, GPR75

The cellular mechanisms underlying the bioactions of 20-HETE have been extensively studied; however, what remains to be elucidated is the up-stream factors that result in the initiation of 20-HETE’s signaling cascade. The first report to demonstrate 20-HETE’s proximal signaling was published by Garcia and
colleagues (2017). They were the first to show that 20-HETE binds to a cell surface receptor, namely GPR75, and to report the proximal signaling mechanism through which 20-HETE causes hypertension and vascular dysfunction (Garcia et al., 2017).

GPR75 is a 7-transmembrane G-protein coupled receptor (GPCR) that is classified as an orphan receptor (Garcia et al., 2017). The gene for this receptor was identified on the 2p16 chromosome and translation of this gene results in a 540 amino acid GPCR with a molecular weight of 59 kDa (Tarttelin et al., 1999). A unique feature of this receptor is its c-terminal tail that is 169 amino acids in length, which is longer than most GPCRs (Pease, 2006). The extended tail allows for docking of proteins to initiate complex signaling cascades. In several different cell models, GPR75 has been shown to complex with Gq, hic-5, c-Src and GIT-1 (Ignatov et al., 2006; Garcia et al., 2017).

The expression of GPR75 can be found in the retinal pigmented epithelium, brain and heart (Tarttelin et al., 1999; Dedoni et al., 2018; Gonzalez-Fernandez et al., 2020). GPR75 expression is also detected in the vascular endothelium and smooth muscle (Garcia et al., 2017; Gonzalez-Fernandez et al., 2020), pancreatic islets (Liu et al., 2013) and prostatic cancer cells (Cárdenas et al., 2020). Within these cell types, it has been shown that activation of GPR75, mediated by Gq, increases intracellular calcium which then activates downstream signaling including phospho-ERK1/2 (Ignatov et al., 2006; Garcia et al., 2017; Dedoni et al., 2018; Cárdenas et al., 2020). Garcia et al. (2017), demonstrated that in VSMCs 20-HETE-GPR75 pairing results in a PKC- and c-Src-mediated
phosphorylation of BK$_{Ca}^{2+}$ channels leading to their inactivation (Garcia et al., 2017).

The effects of 20-HETE on the cardiovascular system through its binding to GPR75 is a new area of research. There is evidence that individuals with a permutation of the 2p chromosome (the site of GPR75 gene) are more likely to be non-responders to current hypertensive therapies (Padmanabhan et al., 2006). Thus, exploring the effects of GPR75 on blood pressure can be useful. Garcia et al. (2017) showed that mice with overexpression of Cyp4a12 were hypertensive and knocking down GPR75 with shRNA normalized blood pressure (Garcia et al., 2017). Furthermore, pharmacological antagonism of the 20-HETE-GPR75 pairing has been shown to blunt 20-HETE-dependent actions in the cardiovascular system as well as in disease models (Pandey et al., 2017; Gilani et al., 2018, 2021; Soler et al., 2018). In a report by Sedláková et al. (2018), they generated a rat model with elevated 20-HETE and angiotensin II that dramatically increased the blood pressure. They administered AAA (a novel 20-HETE receptor antagonist) which was able to lower the blood pressure of these rats (Sedláková et al., 2018). In another report, AAA was shown to blunt the effects of 20-HETE on the metastatic features in a prostate cancer cell line (Cárdenas et al., 2020). Thus, pharmacological antagonism may be a therapeutic strategy for the treatment of 20-HETE-related diseases.
20-HETE and hypertension

The link between 20-HETE and hypertension has been well established across numerous animal models. The use of animal models has been vital in understanding the actions of 20-HETE in vivo. Animal models have shown the consequences of elevated 20-HETE levels on vascular and renal function. Some examples of animal models include: 1) Cyp4a12-tg, 2) DHT-pellet-treated mice, 3) Cyp4a14\textsuperscript{-/-}, 4) spontaneously hypertensive rats, and 5) Dahl salt-sensitive hypertensive rats.

The Cyp4a12-tg mouse has elevated 20-HETE production in the presence of doxycycline (CC Wu et al., 2013). This mouse was engineered to have Cyp4a12 expression controlled by the tetracycline inducible promoter. This is advantageous in experiments where control of 20-HETE production is necessary. Administration of doxycycline (DOX) in these mice resulted in changes in blood pressure and vascular reactivity that are dependent on 20-HETE (CC Wu et al., 2013; Ding et al., 2013; Gilani et al., 2021).

Androgens are a known inducer of Cyp4a expression and 20-HETE. Two animal models of androgen-inducible 20-HETE include the DHT-pellet-treated mouse and the Cyp4a14\textsuperscript{-/-} mouse. DHT-pellets are implanted subcutaneously in the mouse which allows for global overproduction of Cyp4a12 and 20-HETE that can be observed in male and female mice (Singh et al., 2007; CC Wu et al., 2013; Garcia et al., 2015a). The Cyp4a14\textsuperscript{-/-} mouse also resulted in increased Cyp4a12 and 20-HETE. The deletion of the Cyp4a14 gene promotes androgen-driven Cyp4a12 expression that is only observable in male mice (CC Wu et al.,
2013; Ding et al., 2013; Pandey et al., 2017). Both these experimental models are associated with elevation in blood pressure, altered vascular function and kidney function.

The Tie2-CYP4F2-Tr mouse is a genetically engineered mouse that displays overexpression of the human CYP4F2 gene specifically in EC (Cheng et al., 2014). These mice have elevated 20-HETE in EC of tissues including kidney, lung, liver, heart and aorta. The Tie2-CYP4F2-Tr displayed changes in the angiogenic phenotype but do not have any differences in blood pressure compared to wild type mice (Cheng et al., 2014).

The spontaneously hypertensive rat (SHR) is documented to have elevated Cyp4a1, Cyp4a2, and Cyp4a3 levels which all contribute to the elevation of 20-HETE (Sacerdoti et al., 1989; Roman, 2002; Dunn et al., 2008). This rat model has been documented to have increases in blood pressure, vascular reactivity and changes in cerebral and renal blood flow (Zhang et al., 2001; Dunn et al., 2008). The changes in cerebral circulation were associated with cerebral infarcts (Dunn et al., 2008).

The Dahl salt-sensitive hypertensive rat is an example of an animal model where lower 20-HETE levels result in elevated blood pressure. In the medullary area of the kidney, Cyp4a expression was reduced (Stec et al., 1996). Reductions in Cyp4a and 20-HETE were associated with changes in transluminal voltage due to uninhibited activity of the NKCC2 cotransporter (Roman and Kaldunski, 1991; Ito and Roman, 1999). This increased salt and fluid
reabsorption which contribute to the elevation in blood pressure (J Wu et al., 2013).

Hypertension is defined as the chronic elevation of blood pressure, >130/80 mmHg (CDC, 2020). In the United States, nearly half of adults fit into this definition with men, African Americans and/or Hispanics having a greater risk of developing hypertension (CDC, 2020). Individuals with elevated blood pressure are at a greater risk of coronary heart disease, stroke, and renal failure (Gosmanova et al., 2016). Current therapies, such as ACE inhibitors, diuretics, beta-blockers, and calcium channel blockers target their respective signaling mechanism to reduce blood pressure. However, approximately one-third of the population do not see a successful outcome from using hypertensive medications (Cushman et al., 2002). Thus, new therapies are in need to improve the clinical outcome within these patients.

CYPs are well known to have genetic variations that are correlated with increasing blood pressure in humans (Rocić and Schwartzman, 2018). Genetic polymorphisms have been shown to change the catalytic activity of these enzymes. For example, the T8590C SNP for CYP4A11 and the V433M in CYP4F2 have been shown to be associated with hypertension (DE Stec et al., 2007; Laffer et al., 2008; Ward et al., 2008; Huang et al., 2020). Changes in catalytic activity of these enzymes may affect 20-HETE levels which drives the changes in blood pressure. 20-HETE has been shown to correlate with certain factors in hypertensive patients. 20-HETE has been shown to positively correlate
with blood pressure in patients with salt-sensitive hypertension (Laffer \textit{et al.}, 2003), and negatively correlate with flow-dependent dilation (Ward \textit{et al.}, 2004).

The effects of 20-HETE on blood pressure and sodium handling are complex. On one hand, it inhibits ion transport along the nephron leading to natriuresis thus contributing to anti-hypertensive mechanisms. For example, Dahl salt-sensitive hypertensive rats are known to have decreased Cyp4a expression and 20-HETE production which is associated with higher blood pressure (Stec \textit{et al.}, 1996). 20-HETE in the kidney tubule has been shown to inhibit the NKCC2 co-transporter, which is occurring at a lower frequency in the Dahl salt-sensitive rat (Escalante \textit{et al.}, 1991, 1994; Ito and Roman, 1999). On the other hand, global overexpression models of 20-HETE, including 5-dihydrotestosterone treated mice (Ding \textit{et al.}, 2013), Cyp4a12 transgenic mice (Garcia, \textit{et al.}, (2015b)), and the Cyp4a14\(^{+/−}\)-knock out mouse (Holla \textit{et al.}, 2001; CC Wu \textit{et al.}, 2013) all have been shown to promote vasoconstriction and increases in peripheral vascular resistance and blood pressure due to systemic elevations of 20-HETE.

The proposed studies are aimed at identifying the cellular mechanism (GPR75-mediated) by which 20-HETE affects VSMC contractility and determining the role of VSMC-derived 20-HETE in the control of blood pressure. The influence of 20-HETE in the regulation of blood pressure makes it an attractive target for therapeutic intervention. The discovery of GPR75 as the 20-HETE receptor provides a specific therapeutic site to target 20-HETE bioactions.
Hypothesis

Smooth muscle-specific overexpression of Cyp4a12-20-HETE-synthase results in hypertension and impaired vascular function that is 20-HETE-dependent
Specific Aims

Aim 1: To determine if smooth muscle-specific overexpression of Cyp4a12-20-HETE synthase (Myh11-4a12) causes hypertension and vascular dysfunction

a) Establish transgenic mice with smooth muscle-specific overexpression of the Cyp4a12-20-HETE synthase (Myh11-4a12).

b) Characterize the phenotype of the Myh11-4a12 with respect to blood pressure and vascular function including contractility, vasodilatory response and remodeling.

Aim 2: To determine if the hypertension and vascular pathology in Myh11-4a12 mice are 20-HETE-dependent

a) Use a 20-HETE receptor antagonist to determine whether the hypertensive and vascular phenotype of the Myh11-4a12 mice are 20-HETE dependent

Aim 3: To explore cellular mechanisms underlying the changes in vessel reactivity of arteries from mice with smooth muscle-specific overexpression of Cyp4a12

a) Assess expression of known 20-HETE targets (e.g., eNOS, ACE, Rho-kinase, MLC) in vascular beds including renal microvessels and mesenteric arteries by qRT-PCR and Western blot.
b) Examine whether activation of the Rho-kinase underlies the contractile phenotype of arteries from *Myh11-4a12* mice using pressure myography, 20-HETE receptor antagonists and a Rho-kinase inhibitor.
Materials and Methods

Animals: Mice with VSMC-specific overexpression of Cyp4a12 were generated by crossing mice with cre-recombinase expression driven by the VSMC-specific myosin heavy chain promoter (Myh11-Cre\textsuperscript{+/−}) and Cyp4a12-flox mice (Cyp4a12-flox\textsuperscript{+/−}). Cyp4a12-flox\textsuperscript{+/−} mice contain loxP sites flanking a regulatory region of the Cyp4a12 promoter. In the presence of cre-recombinase, the regulatory region is removed and unregulated Cyp4a12 production can occur. Pups generated were divided into wild type (WT: Myh11-4a12-Cre\textsuperscript{+/−}-Cyp4a12-flox\textsuperscript{+/−}) or positive mice (Myh11-4a12: Myh11-Cre\textsuperscript{+/−}-Cyp4a12-flox\textsuperscript{+/−}). All mice were housed in static cages and fed standard chow. Experiments were conducted on mice between the ages of 2-4 months. A novel water-soluble 20-HETE receptor antagonist, N-disodium succinate-20-hydroxyeicosa-6(Z),15(Z)-diencarboxamide (AAA), was used to assess the relevance of 20-HETE in the phenotype of these mice. Mice were divided into three groups: 1) Wild-type – vehicle; 2) Myh11-4a12 – vehicle; and 3) Myh11-4a12 – AAA treatment. Baseline SBP was measured before administration of AAA. Mice were administered either vehicle (tap water) or AAA at a dose of 10mg.kg\textsuperscript{−1}.day\textsuperscript{−1} in drinking water. Systolic blood pressure was measured on days 0, 4, 8, and 12. After the last blood pressure measurement, mice were sacrificed and tissues were collected for physiological and biochemical analysis.

Blood Pressure Measurements: Systolic blood pressure (SBP) was measured using CODA non-invasive tail-cuff method (Kent Scientific, Torrington, CT). The
CODA tail-cuff system utilizes volume-pressure recording (VPR) technology to measure the expansion of the mouse’s tail due to the return of blood flow after occlusion. All cuffs and bladders were checked for patency before measurements were taken. A warming plate was set to 32-35°Celsius to maintain body temperature during the measurement. The CODA software was set to have a deflation time of 20 seconds and allowed measurements of ≥ 15µL. Mice underwent 30 inflation-deflation cycles. The first 5 cycles were dedicated for acclimation and was not used in blood pressure determination. The last 25 cycles were used for blood pressure measurements. All cycles were carefully examined and cycles were removed if artifacts were identified in the measurement. All mice were allowed 5-7 days to undergo the tail-cuff procedure without collecting data. Baseline measurements per mouse were obtained by taking the average SBP on three separate days. Blood pressure measurements on AAA were measured on days 0, 4, 8, and 12. The CODA system is able to measure SBP within ±10% of actual value.

**Wired Myography:** Phenylephrine-induced contraction, as well as acetylcholine and SNP induced relaxation were performed on renal interlobar arteries (RIA). Kidneys were taken out of mice and were carefully dissected in a dish containing Kreb’s buffer. Isolated vessels were mounted onto wires in a chamber of a multivessel myograph. Before conducting experiments, vessels were allowed to sit in a bath containing Kreb’s buffer, maintained at 37°C, and constantly being bubbled with 95/5% O₂/CO₂ for 30-60 minutes. All vessels were set to an internal
circumference that is 90% of what the circumference would be at 100mmHg. Isometric tension was measured throughout the experiment. Cumulative phenylephrine dose-response experiments were performed. Phenylephrine was administered at half-dose intervals from \((10^{-9} - 10^{-4})\) M directly into the tissue bath. Tension was represented as a percentage of the maximal response at \(10^{-4}\) M phenylephrine. Percent maximal response \(\% = [(\text{tension at a dose Phe/} (\text{tension}\ 10^{-4}\ \text{M Phe - baseline tension})]*100\]. Acetylcholine or sodium nitroprusside (SNP) relaxation experiments were also performed. Before acetylcholine or SNP administration, precontraction was achieved by administering phenylephrine \(10^{-6}\) M to the vessel bath. Acetylcholine \(10^{-8} - 10^{-4}\) M or SNP \(10^{-9} - 10^{-5}\) M was administered in a cumulative dose-dependent fashion after phenylephrine induced precontraction. The percent relaxation was calculated by subtracting the tension after a dose of acetylcholine or SNP from the tension generated from \(10^{-6}\) M phenylephrine, divided by the difference between the baseline tension and \(10^{-6}\) M phenylephrine. Percent relaxation \(\% = [(\text{tension at a dose of Ach or SNP [M] - tension at [10^{-6} M Phe]/ (tension at [10^{-6} M Phe - baseline tension])*100}]\).

**Pressure Myography:** Renal interlobar arteries were dissected in the same manner as for wired myography experiments. Living Systems Instrumentations (St. Albans City, VT) pressure myograph was used to induce pressures within the lumen of the vessel. The distances of the inner and outer diameters were measured using video edge detection. One end of the renal interlobar artery was mounted onto a glass canula and the other side was ligated closed. The vessel
was allowed to equilibrate for one hour at 37°C in Kreb’s buffer bubbled with 95/5% O2/CO2. For measurements of vascular wall thickness, internal pressures of 100mmHg were induced on normotensive vessels and 140mmHg on hypertensive vessels. Measurements of outer diameter (OD) and inner diameter (ID) under passive conditions were used to calculate media thickness [(OD - ID)/2], media:lumen ratio [(OD - ID)/ID], and medial cross-sectional area [CSA (π/4) x (OD2 - ID2)]. For measurements of myogenic response, only WT vessels were used. Each vessel underwent 5 consecutive treatments in the following order: 1) vehicle only (100% ethanol), 2) 20-HETE (10 μM), 3) 20-HETE + AAA (10 μM), 4) 20-HETE + Rho-kinase inhibitor (Y-27632, 10 μM), and 5) 20-HETE + AAA + Rho-kinase inhibitor. Passive stretch of vessels was also assessed immediately after the treatments by measuring the internal diameter of the vessel in a calcium-free Kreb’s solution. Vessels were subjected to pressures of 0, 20, 40, 60, 80 and 100 mmHg and ID was measured at each pressure. The Absolute and normalized ID were determined after experiments were concluded. The normalized ID was represented as a percentage and calculated as follows: normalized ID = (absolute ID/passive ID)*100.

**Sodium Excretion Studies:** On the last day of AAA treatment, mice were individually housed in metabolic cages to collect urine (Hatteras instruments). Twenty-four-hour urine collection was taken and urine samples were stored at -80°C until time to measure urinary sodium. Water consumption and urine volume
were measured to assess fluid balance. Urinary sodium measurements were performed using flame photometry.

**Western blots:** Mesenteric arteries were taken out and carefully dissected in ice-cold MOPS buffer to remove fat tissue. Vessels were flash-frozen in liquid nitrogen and stored at -80°C. Tissues were lysed by crushing vessels in liquid nitrogen followed by homogenization in RIPA buffer containing protease and phosphatase inhibitor. Lysates were allowed to sit on ice for 15 minutes before centrifugation. Lysates were spun at 10,000 RPM for 15 minutes at 4°C and supernatant was collected for western blot experiments. Protein estimation was performed using BCA assay. Equal amounts of protein were loaded onto a 10%-polyacrylamide gel and ran at 125V. Proteins were transferred onto a PVDF membrane using methanol-glycine-tris-base transfer buffer. After transfer, membranes were blocked in TBS buffer containing 1% bovine serum albumin for 1 hour. Cyp4a (1:1000 – Santa Cruz – cat#: sc-271983), Myh11 (1:1000 – Abcam – cat#: ab125884), ROCK1 (1:1000 – Sigma – cat#: HPA007567), Serine 1177 p-eNOS (1:100 – cell signaling technology – cat#: 9571S), total eNOS (1:100 - BD bioscience – cat#: 610297), β-Tubulin (1:2000 - Invitrogen - cat#: MA5-16308) and β-actin (1:5000 - Cell Signaling Technology – cat#: 4967) were diluted in 1% casein/TBST solution and membranes were submerged in the antibody solution overnight on a shaker at 4°C. Secondary antibodies (Li-Cor biotechnology) were diluted (1:15,000) in 1% casein/TBST solution and membranes were allowed to incubate for 2 hours at room temperature on a
Membranes were visualized on the Li-Cor Odyssey Clx membrane scanner and quantified using ImageStudio software version 5.2.5. All western blots were represented as a fold changed compared to wild type. To calculate this, first the ratio between the protein of interest and the loading control (β-actin or β-tubulin) was determined. The ratio for the WT was then averaged. Lastly, WT and experimental samples were all divided by the average WT ratio to determine the fold change.

For phospho-myosin light chain western blotting, vessels were dissected then placed in 5% trichloroacetic acid/acetone solution and immediately placed in a -80°C freezer until time to homogenize tissue. On the day of tissue homogenization, vessels were taken out of the freezer and allowed to thaw at room temperature for 30 minutes. After 30 minutes, vessels were moved into a 100% acetone solution and sat at room temperature for 30 minutes. Vessels were taken out and weighed so that an approximately equal mass of vessel could be used. Vessels were homogenized in 50 μL of solution containing: 8M urea, 20mM tris-base, 22mM glycine, 10mM DTT, 5mM EGTA, 5mM Na₂EDTA. Samples were spun at 10,000 RPM for 15 minutes at room temperature. The supernatant was collected and an equal volume was mixed with Lamelli sample buffer and loaded onto a 12% PAGE gel. The gel ran at 125V for two hours. The gel was transferred overnight onto a PVDF membrane in buffer containing: 25mM Tris-base, 192mM glycine, and 20% methanol. The next day, membranes were taken out and blocked in 1% BSA in TBS. Phospho-myosin light chain (cell signaling technology - cat#: 3674S) was diluted in 1% casein/TBST solution.
(1:250) and incubated overnight at 4°C. The next day, membranes were incubated in Li-Cor secondary antibody (1:15,000) in 1% casein/TBST buffer for 2 hours. Membranes were visualized on the Li-Cor Odyssey Clx membrane scanner and quantified using ImageStudio software version 5.2.5. Immediately after membrane visualization, membranes were stripped using Li-Cor NewBlot IR stripping buffer according to manufacturer’s protocol. Membranes were blocked with 1% BSA/TBS blocking buffer for 1 hour followed by incubation with myosin light chain antibody (1:250 - cell signaling technology - cat#: 3672S) in 1% casein/TBST solution. Secondary antibody incubation and quantification was performed the same as for phospho-myosin light chain. The values were represented as a fold change using the same calculations as described above.

**Reverse Transcription Polymerase Chain Reaction:** Mesenteric arteries and RIA were dissected and flash frozen in liquid nitrogen and stored at -80°C. Messenger RNA was obtained using the miRNeasy micro kit (Qiagen – cat: 217084). Equal amounts of RNA were used to generate cDNA using the Quantitech cDNA synthesis kit (Qiagen). Taqman primer/probes for Cyp4a12 (Mm00514494_m1), Myh11 (Mm00443013_m1), Tagln (Mm00441661_g1), Acta2 (Mm00725412_s1); Col4a4 (Mm00801574_m1); Col1a1 (Mm00801666_g1), Ace (Mm00802048_m1), and Tuba1a (Mm00846967_g1) were purchased from ThermoFisher. For all reactions, 2 μl cDNA was mixed in 18 μl of master mix containing: 1 μl of 20X primer/probe, 10 μl 2X Taqman advance fast master mix and 7 μl nuclease free water. The thermal profile for
qPCR reaction was: 50°C for 2 minutes, 95°C for 20 seconds and 40 cycles of 95°C for 3 seconds and 60°C for 30 seconds. Relative expression was calculated using the $2^{\Delta\Delta \text{Ct}}$ method. Ct values were determined using the QuantStudio 3 RT-PCR machine for all genes of interest. The change in Ct ($\Delta \text{Ct}$) values were determined by taking the difference between the experimental gene from the housekeeper gene (Tuba1a). After the determination of the $\Delta \text{Ct}$, the $\Delta\Delta \text{Ct}$ value was calculated. To do this, the WT $\Delta \text{Ct}$ was averaged. The difference between the $\Delta \text{Ct}$ values for each mouse and the average $\Delta \text{Ct}$ values was determined. Lastly, 2 was raised to the ($-\Delta\Delta \text{Ct}$) to determine the relative expression of the gene of interest.

**20-HETE Measurements:** 20-HETE was quantified by LC-MS/MS-based lipidomics. Blood was withdrawn at the end of the experiment by aspiration from the inferior vena cava. Briefly, animals were anesthetized with isoflurane, and their abdomens were swabbed with 70% alcohol and opened by a midline longitudinal incision. Next, the caudal (inferior) vena cava was identified and punctured, and blood was drawn into a heparinized syringe. Blood was centrifuged at 2,000 rpm for 15 min to separate the plasma. Plasma samples were subjected to chloroform-methanol extraction and alkali hydrolysis for assessment of free and esterified 20-HETE. Renal preglomerular arteries and mesenteric arteries were microdissected and incubated in Kreb’s bicarbonate buffer, pH 7, 1 mM NADPH at 37°C for 1 h. Tissue incubations were terminated with 2 volumes of cold methanol, internal standards were added, and samples
were kept at -80°C. Urine was mixed with two parts of methanol before LC-MS/MS. Eicosanoids were extracted with solid-phase Strata-X Polymeric Reversed Phase 60-mg cartridges (Phenomenex, Torrance, CA). Identification and quantification of 20-HETE were performed on a Shimadzu Triple Quadrupole Mass Spectrometer LCMS-8050 equipped with a Nexera UHPLC using multiple reaction monitoring mode. MS conditions were ionization mode: negative heated electrospray (HESI); applied voltage: -4.5 to approximately -3 kV; nebulizer gas: 3.0 L/min N2; drying gas: 5.0 L/min N2; heating gas: 12.0 L/min air; interface temperature: 400°C; desolvation line temperature: 100°C; heat block temperature: 500°C; and internal standard: d6 20-HETE. UHPLC conditions were as follows: analytical column measures were Zorbax Eclipse Plus C18 RRHD (50-mm length x 2.1-mm inner diameter, 1.8 μm); mobile phase A: 95% water-5% acetonitrile 0.05% acetic acid; mobile phase B: acetonitrile 0.05%; time program 40% B (0 min) → 75% B (3 min) → 85% B (7.5 min); flow rate: 0.4 mL/min; injection volume: 5 μL; column oven temperature: 40°C. Synthetic standards were used to obtain standard curves (0.5–500 pg) for each compound. These standard curves were used to calculate final concentrations of 20-HETE. All solvents were HPLC grade or higher.

**Statistics:** All values are represented as mean ± SEM. Statistical analysis was performed on GraphPad Prism 8 (version 8.4.3). Two-tailed student t-test was used to determine significance between two groups. One-way ANOVA with Tukey post-hoc test was used to compare differences between three or more
means. 2-way ANOVA repeated measures with Sidak’s post hoc test was used for phenylephrine, acetylcholine and sodium nitroprusside dose-response analysis. For wire and pressure myography experiments, both number of mice (N) and number of vessels (n) were reported. Experiments that compared vessel reactivity between two genotypes (WT and *Myh11-4a12* mice) use N for statistical calculations. Experiments that assessed the effectiveness of AAA on acetylcholine induced relaxation within one genotype used n for statistical calculations. EC₅₀ values from phenylephrine cumulative dose response curves were calculated and were compared using one-way ANOVA with Tukey post-hoc test. Rmax values from acetylcholine or SNP induced relaxation were compared using one-way ANOVA with Tukey post-hoc test. p-values <0.05 were considered to be statistically significant.
Results:

Aim 1: To determine if smooth muscle-specific overexpression of Cyp4a12-20-HETE synthase causes hypertension and vascular dysfunction.

Myh11-Cre^{(+/-)}-Cyp4a12-Flox^{(+/wt)} (Myh11-4a12) had significantly elevated Cyp4a12 levels in vessels that resulted in elevated 20-HETE.

Myh11-4a12 mice had a significant increase of Cyp4a12 mRNA expression in resistant vessels (mesenteric arteries: 8.62 ± 1.26 vs 1.44 ± 0.30; RIA: 5.95 vs 1.12, relative expression to Tuba1a, p<0.0001) compared to WT (Figure 1A and 1B). The increase in expression was not observed in liver (Figure 1C: 1.56 ± 0.54 vs 1.91 ± 0.37 relative expression to Tuba1a). The overexpression of mRNA translated to increased Cyp4a protein levels when comparing mesenteric arteries of Myh11-4a12 mice to WT (Figure 2A: 1.95 ± 0.21 vs 1.00 ± 0.21 Cyp4a/β-actin fold expression, p<0.05). Increases in Cyp4a protein expression were not observed in livers (Figure 2B: 1.00 ± 0.15 vs 1.00 ± 0.15, Cyp4A/β-actin fold change). Furthermore, elevated Cyp4a12 was associated with increased 20-HETE levels in mesenteric arteries (3334 ± 891 pg/mg protein vs 545 ± 197 pg/mg protein, p<0.05), RIA (1895 ± 376 pg/mg protein vs 242 ± 63 pg/mg protein, p<0.05), and plasma (391 ± 52 pg/mL vs 242 ± 18 pg/mL, p=0.05) without any changes in urinary levels (117 ± 29 pg/mL vs 146 ± 27 pg/mL, p=0.48) (Figure 3A-D).
**Myh11-4a12 mice are hypertensive and have impaired vascular function.**

Systolic blood pressure (SBP) measured at 8-10-weeks of age was significantly higher in Myh11-Cyp4a12 mice compared to WT mice (Figure 5A: 144 ± 2 vs 130 ± 1 mmHg, p<0.0001). Isolated RIA from Myh11-4a12 mice displayed impaired acetylcholine-induced relaxation after precontraction with phenylephrine compared to RIA from WT mice (Figure 5B: Maximal relaxation: 47% ± 6.9 vs. 80% ± 4.3 p<0.001). Renal interlobar arteries from Myh11-4a12 mice given a NO donor (SNP) were able to relax to a degree similar to WT (Figure 5C: Maximal relaxation: 85% ± 4.0 vs 80% ± 9.0) Measurements of vessel wall thickness were taken to assess 20-HETE’s effects on vascular remodeling. Myh11-4a12 mice had an increase media:lumen ratio compared to WT (Figure 6A: 0.332 ± 0.027 vs 0.164 ± 0.010, p<0.0001, student t-test). Media thickness (Figure 6B: 25.70 ± 1.22 μm vs 15.00 ± 0.71 μm, *p<0.05) and media cross-sectional area (Figure 6C: 15718 ± 1496 μm² vs 10407 ± 660 μm², *p<0.05) were also elevated in Myh11-4a12 mice compared to WT mice.

**Markers of smooth muscle cell contraction and NO signaling were altered in Myh11-4a12 mice.**

20-HETE has been documented to have multiple actions on vessels to increased contractility and impaired relaxation. Phosphorylation of myosin light chain at serine 19 was used as a marker for increased cellular signaling for VSMC contraction. Mesenteric arteries from Myh11-4a12 mice had a 40% increase in phosphorylation of myosin light chain compared to WT mice (Figure 7: 1.40 ± 0.13 vs 1.00 ± 0.08 Ser19 p-MLC/total-MLC fold change, p<0.05).
Phosphorylation of eNOS was used as a marker for EC cell function and enhanced relaxation. In aortas of *Myh11-4a12* mice, there were reductions in both phosphorylated and total eNOS expression that was significantly lower than WT mice (Figure 8: 0.43 ± 0.19 vs 1.23 ± 0.26 Serine 1177/β-tubulin fold change, *p<0.05 and 0.57 ± 0.14 vs 1.00 ± 0.08 total eNOS/ β-tubulin fold change).
Figure 1: *Myh11-4a12* mice display overexpression of *Cyp4a12* in vessels.

RT-PCR result: A) mesenteric artery (N=14/group; ***<0.001 student t-test), B) RIA (N=6/group, *<0.05 t-test) and C) Liver (N=6 wild type, n=7 *Myh11-4a12*)
Figure 2: *Myh11-4a12* mice have elevated Cyp4a protein in vessels.

A) Mesenteric artery (N=4/group, *p<0.05 compared to wild type, student t-test) but no difference was observed in B) liver (N=8/group, student t-test).
Figure 3: Myh11-4a12 mice display elevated 20-HETE.

A) Mesenteric arteries (N=5 WT, n=6 Myh11-4a12), B) RIA (N=3/group), C) Plasma (N=4 WT, N=6 Myh11-4a12) but not in D) Urine (N=5/group). Mean ± SEM student t-test *p<0.05.
Figure 4: Mice with smooth muscle-specific overexpression of *Cyp4a12* are hypertensive.

Baseline systolic blood pressure measurement. N=22 Wild type; N=27 *Myh11-4a12*. ****p<0.0001, student t-test.
Figure 5: Mice with smooth muscle-specific overexpression of \textit{Cyp4a12} have impaired relaxation.

A) Acetylcholine-induced relaxation after phenylephrine precontraction. Wild type N=13 mice, n=26 vessels and \textit{Myh11-4a12} N=15 mice, n=28 vessels. 

\*\*\*p<0.001, t-test. B) Administration of SNP improved relaxation of vessels with overproduction of 20-HETE. Wild Type: n=3 mice; \textit{Myh11-4a12}: n=4 mice. t-test. Means ± SEM,
Figure 6: Renal interlobar artery measurements of vascular remodeling are elevated in *Myh11-4a12* mice.

A) Media:lumen ratio, B) Media thickness, and C) Media cross-sectional area. Wild type N=12 mice, n=24 vessels, *Myh11-4a12* N=14 mice, n=28 vessels; **p<0.01, ***p<0.0001, student t-test.
Figure 7: Baseline expression of myosin light chain phosphorylation at serine 19 in mesenteric arteries were elevated in Myh11-4a12 mice.

N=12 wild type; N=10 Myh11-4a12. *p<0.05 student t-test.
Figure 8: Baseline expression of phosphorylated and total eNOS was reduced in aortas of Myh11-4a12 mice.

A) Serine 1177 phosphorylated eNOS to β-tubulin ration and B) total eNOS to β-tubulin. N=6/group, *p<0.05, student t-test
Aim 2: To determine if the vascular pathology in Myh11-4a12 mice is 20-HETE-dependent.

Administration of AAA decreased systolic blood pressure and improved vascular function in mice with smooth muscle-specific Cyp4a12 overexpression.

Myh11-4a12 mice were hypertensive compared to WT on day 0 (Figure 9: Myh11-4a12 (combine): 146 ± 3 mmHg vs WT – vehicle: 132 ± 3 mmHg, p<0.001, student t-test). Twelve days of AAA treatment normalized SBP to WT levels with values starting to decrease at day 4 (Day 12: Myh11-4a12 – AAA 126 ± 1 vs 129 ± 1 mmHg). Wild type mice on AAA had no changes in SBP compared to WT mice on vehicle (data not shown). Administration of AAA appeared to have no effect on 20-HETE levels in the plasma. Myh11-4a12 mice had elevated 20-HETE levels compared to WT (Figure 10: 298 ± 35 vs 157 ± 23 pg/mL plasma, p<0.05) however, Myh11-4a12 mice on AAA (298 ± 58 pg/mL plasma) had a similar value compared to Myh11-4a12 mice on vehicle.

Fluid balance and urinary sodium excretion was also assessed to determine if the blood pressure lowering effect of AAA was also due to changes in the renal handling of salt and fluid. Mean values for water consumption appeared similar between the three groups (Figure 11A: Wild type – vehicle: 0.38 vs Myh11-4a12 – vehicle: 0.38 vs Myh11-4a12 – AAA 0.37 mL/gram body weight/24 hours). Urine volume was similar between WT and Myh11-4a12 mice on vehicle (Figure 11B: 52.0 vs 55.6 μL/gram body weight/24 hours). Urine
excretion appeared to increase in *Myh11-4a12* mice on AAA (75.6 μL/gram body weight/24 hours), however, no conclusion was made due to the small sample size. Similar trends were observed when measuring urinary sodium excretion. Average values for urinary sodium excretion were similar between *Myh11-4a12* and WT mice on vehicle (6.91 μmole/gram body weight vs 7.71 μmole/gram body weight/24 hours). While there was an upward trend in sodium excretion in *Myh11-4a12* mice on AAA, no conclusions could be determined due to the small sample size (11.35 μmole/gram body weight/24 hours).

After day 12, mice were sacrificed and RIA were isolated for wire myography. RIA from *Myh11-4a12* mice displayed impaired acetylcholine-induced relaxation compared to WT mice (Rmax: 67% ± 5 vs 90% ± 2, \(P<0.0001\)). *Myh11-4a12* mice on AAA had improved acetylcholine relaxation with values similar to WT (Rmax: 96% ± 1) (Figure 12A). Changes in phenylephrine-induced contractions were also observed. RIA from *Myh11-4a12* mice were more sensitive to phenylephrine-induced contraction compared to WT (EC\(_{50}\): 1.63 x 10\(^{-7}\) μM vs. 5.00 x 10\(^{-7}\) μM, \(p<0.0001\)). The sensitivity of phenylephrine for *Myh11-4a12* mice on AAA (EC\(_{50}\): 4.22 x 10\(^{-7}\) μM) was not different compared to WT (Figure 12B).

*Ex vivo* experiments were performed to assess the direct actions of AAA in RIA to promote relaxation. Both WT and *Myh11-4a12* vessels were treated with vehicle first followed by 10 μM AAA. Wild type vessels had no apparent difference in the ability to relax after acetylcholine-induced relaxation (Figure 13A). On the other hand, *Myh11-4a12* mice displayed improved relaxation
response after acetylcholine administration. Myh11-4a12 vessels had a maximal % relaxation of 40 ± 6% after vehicle treatment. AAA pretreatment resulted in improved relaxation (63 ± 7%, p<0.05) (Figure 13B). Comparisons were made between the four groups at the highest does of acetylcholine administration. Myh11-4a12 vessels on vehicle had significantly impaired relaxation response compared to WT either on vehicle or AAA (Figure 13B: 40 ± 6% vs. 67 ± 6 WT – vehicle and 64 ± 6% WT – AAA, p<0.05). AAA was able to significantly improve the ability of the vessels to relax in Myh11-4a12 mice. Myh11-4a12 vessels after AAA had similar relaxation values compared to WT on vehicle or AAA (Figure 13C: 63 ± 4%)

AAA administration improved media:lumen ratio but did not affect media thickness or cross-sectional area of RIA

Renal interlobar arteries from Myh11-4a12 mice had a media:lumen ratio that was significantly higher than WT (Figure 14A: 0.277 ± 0.025 vs 0.163 ± 0.006, P<0.0001). RIA from AAA-treated Myh11-4a12 mice showed a reduction in media:lumen ratio (0.129 ± 0.013, p<0.05) when compared to Myh11-4a12 on vehicle (Figure 14A). Analysis of media wall thickness and media cross-sectional area show that AAA did not have an effect on vessel wall thickness. Both Myh11-4a12 mice either on vehicle or AAA had a thicker media (Figure 14B: 23.85 ± 2.25 μm and 20.72 ± 1.37 μm vs 15.86 ± 0.83 μm, p<0.0001 WT - vehicle vs Myh11-4a12 - vehicle and p<0.05 WT - vehicle vs Myh11-4a12 – AAA) and cross-sectional area (Figure 14C: 15114 ± 1871 μm² and 14268 ± 1259 μm² vs
10560 ± 641 μm², p<0.05 WT - vehicle vs Myh11-4a12 - vehicle and p=0.08 WT - vehicle vs Myh11-4a12 – AAA) compared to WT. Western blot analysis for myosin heavy chain 11, a marker of vascular smooth muscle cell differentiation, is in line with these results. Myh11-4a12 mice either on vehicle or AAA appeared to have higher myosin heavy chain expression compared to WT on vehicle (Figure 14D: 3.10 ± 0.98 Myh11/β-tubulin fold change and 3.25 ± 0.72 Myh11/β-tubulin fold change vs 1.00 ± 0.10 Myh11/β-tubulin fold change).

**Markers of VSMC differentiation were elevated in Myh11-4a12 mice.**

At baseline, the vessel wall was thicker in Myh11-4a12 mice compared to WT mice. This may be due to 20-HETE’s ability to cause VSMC proliferation which increases the number of mature cells within the vessel wall. To determine this, markers of VSMC differentiation [Myh11, Sm22a, Acta2] were measured in renal interlobar arteries (Figure 15). Myh11 (RIA: 1.67 ± 0.22 vs 1.18 ± 0.22, relative expression to tuba1a), Tagln (2.13 ± 0.25 vs 1.17 ± 0.26 relative expression to tuba1a, p<0.05 t-test), and Acta2 (RIA: 1.94 ± 0.23 vs 1.14 ± 0.20, relative expression tuba1a, p<0.05 t-test) mRNA expression were all elevated compared to WT mice.
No differences in collagen expression were observed between *Myh11-4a12* and wild type mice.

20-HETE has been documented to promote increases in collagen synthesis in rats (Soler *et al.*, 2018). Messenger RNA of Collagen I and Collagen IV were assessed to determine if increase in collagen synthesis was occurring which may contribute to the stiffening of the vessels and increase in blood pressure. Collagen I (0.76 ± 0.28 vs 1.25 ± 0.25, relative expression to *Tuba1a*) and collagen IV (1.12 ± 0.29 vs 1.25 ± 0.30, relative expression to *Tuba1a*) were not different between *Myh11-4a12* and WT mice in mesenteric arteries (Figure 16).
Figure 9: Administration of a 20-HETE receptor antagonist (AAA) was able to lower blood pressure after 12 days.

A) Wild Type or Myh11-4a12 mice underwent either vehicle treatment or AAA (10mg/kg/day) treatment for 12 days. N=12 Wild type – vehicle; N=11 Myh11-4a12 – vehicle; N=14 Myh11-4a12 – AAA. *p<0.05 of Myh11-4a12 compared to wild type. #p<0.05 Myh11-4a12 – vehicle to Myh11-4a12 – AAA. 2-way ANOVA with Tukey post-hoc test.
Figure 10: Plasma 20-HETE levels were unchanged after 12-day AAA treatment.

Wild type - Vehicle N=13, Myh11-4a12 - Vehicle N=15, Myh11-4a12 – AAA N=10. *p<0.05 one-way ANOVA vs wild type - vehicle.
Figure 11: Urine volume and sodium excretion in WT and $Myh11$-4a12 mice treated with and without AAA.

A) water consumption, B) urine volume, C) urinary sodium. Wild type – vehicle N=3, $Myh11$-4a12 - vehicle N=2, $Myh11$-4a12 – AAA N=3.
Figure 12: Vascular activity was improved after 12 days of AAA treatment.

A) Dose response acetylcholine induced relaxation on RIA after 12 days of AAA treatment. Wild Type – vehicle N=7 mice, n=14 vessels; Myh11-4a12 – vehicle N=7 mice, n=14 vessels; Myh11-4a12 – AAA N=7 mice, n=14 vessels. ***p<0.001 Wild Type - vehicle vs Myh11-4a12 -vehicle; ###p<0.0001 Myh11-4a12 - vehicle vs Myh11-4a12 – AAA. One-way ANOVA.

B) Dose response phenylephrine induced contraction on RIA after 12 days of treatment. Wild Type – Vehicle N=7 mice, n=14 vessels; Myh11-4a12 – vehicle N=9 mice, n=18 vessels; Myh11-4a12 – AAA N=6 mice, n=12 vessels. ***p<0.001, ##p<0.01 One-way ANOVA
Figure 13: *Myh11-4a12* mice had improved relaxation with AAA treatment *ex vivo*.

A) Wild type N=3 mice, n=9 vessels. B) *Myh11-4a12* N=6 mice, n=17 vessels vehicle and n=16 vessels AAA treatment. *p<0.05 2-way ANOVA. C) comparisons of all treatments at 10^{-4}M acetylcholine. P<0.05 one-way ANOVA.
Figure 14: Myh11-4a12 mice have an elevated media:lumen ratio that was reduced with AAA treatment, however, AAA did not reduce the thickness of the vessel.

Renal interlobar arteries underwent pressurized myography and the inner and outer diameters were measured. A) media:lumen ratio; B) media thickness; C) media cross-sectional area (CSA). Wild type – vehicle N=9 mice, n=18 vessels Myh11-4a12 – vehicle N=7 mice, n=14 vessels, Myh11-4a12 – AAA N=8 mice, n=16 vessels. Mean ± SEM one-way ANOVA *p<0.05, **p<0.01, ***p<0.001. D) Western blot analysis for smooth muscle-specific myosin heavy in mesenteric arteries. N=5 wild type - vehicle, N=4 Myh11-4a12 – vehicle, N=5 Myh11-4a12 – AAA. Mean ± SEM, one-way ANOVA.
Figure 15: Increases in markers of VSMC differentiation were observed in RIA of Myh11-4a12 mice.

A) Myh11 (N=6/group) B) Tagln (wild type: N=7; Myh11-4a12: N=6); C) Acta2 (N=6/group) Means ± SEM, *p<0.05, **p<0.01, ***p<0.001 student t-test.
Figure 16: No differences in collagen expression were observed between *Myh11-4a12* and wild type mice.

Aim 3: To explore cellular mechanisms underlying the increased contractility of arteries from mice with smooth muscle-specific overexpression of Cyp4a12.

No changes were observed in ACE mRNA expression between wild type and Myh11-4a12 mice.

ACE expression has been shown to increase with elevated 20-HETE. Increases in ACE result in increases in angiotensin II which may have a direct action on vessels to cause contraction. ACE is primarily expressed in the endothelium, however, there is also ACE expression in the VSMC (Fishel et al., 1995). After measuring Ace mRNA in mesenteric arteries, there was no difference between Myh11-4a12 and WT mice (Figure 17: 1.36 ± 0.26 vs 1.03 ± 0.126, relative expression to tuba1a)

Myh11-4a12 mice appeared to have reductions in eNOS activation which was increased with AAA treatment.

Myh11-4a12 mice with elevated 20-HETE have impaired relaxation to acetylcholine, and administration of a 20-HETE receptor antagonist improves the relaxation of the vessel to a level similar to wild type. Furthermore, administration of a NO donor allowed the vessel from Myh11-4a12 mice to relax to a degree similar to WT. This suggests that vessels from Myh11-4a12 mice have an impairment in NO bioavailability. The inhibition of eNOS activation is one possible reason for this impairment. Activation of eNOS was measured by
phosphorylation of eNOS at Serine 1177 via western blotting. Myh11-4a12 mice appeared to have reductions in Serine 1177 phosphorylation compared to wild type in aorta (Figure 18A: 0.43 ± 0.19 vs 1.23 ± 0.26, Ser1177 p-eNOS/β-tubulin fold change). Myh11-4a12 mice also appeared to have lower total eNOS expression compared to WT (Figure 18B: 0.57 ± 0.14 vs 1.00 ± 0.08 total eNOS/β-tubulin fold change). AAA treatment appeared to increase phosphorylation (1.42 ± 0.58, Ser1177 p-eNOS/β-tubulin fold change) and total eNOS (1.20 ± 0.58, total eNOS/β-tubulin fold change) levels of Myh11-4a12 mice to a value greater than WT. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation at Serine 239 was also measured because it is an indicator that NO from the EC is able to reach the VSMC. Myh11-4a12 mice had reductions in VASP phosphorylation compared to WT (0.61 ± 0.09 vs 1.00 ± 0.04, Ser239 p-VASP/total VASP fold change, p<0.01) which was unchanged when Myh11-4a12 mice were given AAA (Figure 18C: 0.63 ± 0.07, Ser239 p-VASP/total VASP fold change). In mesenteric arteries, changes in phosphorylation of eNOS were also observed. Myh11-4a12 mice appeared to have reduced eNOS phosphorylation (Figure 19: 0.57 ± 0.06 vs 1.00 ± 0.23 Ser1177 p-eNOS/total eNOS, p=0.15) and Myh11-4a12 mice that were given AAA had increase phosphorylated eNOS levels (1.07 ± 0.08 p-eNOS/total eNOS, p=0.20). Unlike aortas, there were no differences in total eNOS protein expression between the three groups.
Administration of the 20-HETE receptor antagonist was able to reduce phosphorylation of myosin light chain.

20-HETE’s ability to change the sensitivity of RIA to phenylephrine suggests that 20-HETE can mediate actions to cause changes in phosphorylation state of myosin light chain. When probing for the phosphorylation of Serine 19 on the regulatory subunit of myosin light chain, there was approximately a 60% increase in the Myh11-4a12 group compared to wild type (1.60 ± 0.23 vs 1.00 ± 0.06 Ser19 p-MLC/total MLC fold change, p<0.05 one-way ANOVA). Myh11-4a12 mice treated with AAA had reduced phospho-myosin light chain levels (0.94 ± 0.11, Ser19 p-MLC/total MLC fold change, p<0.05 vs Myh11-4a12 – vehicle, one-way ANOVA) that were similar to wild type (Figure 20).

20-HETE was able to increase Rho-kinase activity which was attenuated with AAA.

Upstream of myosin light chain is Rho-kinase (ROCK). RhoA-GTP activates ROCK which causes the phosphorylation and inhibition of myosin light chain phosphatase. Inhibition of myosin light chain phosphatase allows for the phosphate group on myosin light chain to stay on so it remains in a contractile state. ROCK1 protein was measured in RIA and there was a 60% increase in Myh11-4a12 mice compared to wild type (Figure 21: 1.60 ± 0.21 vs 1.00 ± 0.18, p<0.05). AAA treatment did not affect the protein expression of ROCK1 (data not shown). Although AAA was not able to decrease ROCK1 expression, it is
possible that AAA can change activity of ROCK. To assess this, WT RIA
treatments were used and pressure myography was performed to assess AAA and ROCK inhibitor, Y-27632, on 20-HETE-induced changes in myogenic response. Treating RIA with 20-HETE produced a downward shift in the absolute ID and the normalized ID curves (Figure 22 A&B). Co-treatment with 20-HETE plus AAA or ROCK inhibitor (Y-27632) shifted the curve upward overlapping the vehicle treated vessels. Lastly, combined treatment of 20-HETE with AAA and ROCK inhibitor did not result in any further upward shifts in either the absolute ID or normalized ID curves. The most significant changes happened at pressure of 80 mmHg and 100 mmHg (Figure 23). At 80 mmHg, 20-HETE reduced the absolute ID (106 ± 2.5 μm vs 124 ± 2.6 μm, p<0.01) and the normalized ID (42 ± 0.86 % vs 48 ± 0.79%, p<0.001) significantly compared to WT. Co-treatment with 20-HETE plus AAA (absolute ID: 124 ± 2 μm, p<0.001; normalized ID: 48.8 ± 0.89%, p<0.0001) or Y-27632 (absolute ID: 126 ± 3 μm, p<0.001; normalized ID: 49 ± 1.2%, p<0.0001) increase the absolute ID and the normalized ID significantly compared to 20-HETE only. Treatment of RIA with 20-HETE plus AAA and Y-27632 did not produce any further increase in absolute ID (113 ± 4.6 μm, p<0.001 vs 20-HETE treatment) or normalized ID (49 ± 1.4%, p<0.0001 vs 20-HETE treatment). Similar results were observed at 100 mmHg. Administration of 20-HETE in the bath reduced the absolute ID (90 ± 3.3 vs 106 ± 3.2 μm, p<0.05) and the normalized ID (33 ± 1.1 vs 39 ± 0.94%, p<0.01) compared to vehicle treated. Adding either AAA (Absolute ID: 109 ± 3.4 μm, p<0.01; normalized ID: 41 ± 0.97%, p<0.001) or Y-27632 (Absolute ID: 108 ± 3.7, p<0.01; normalized ID: 40 ±
1.1%, p<0.001) blunted the increased myogenic response due to 20-HETE.

Treatment with 20-HETE, AAA and Y-27632 did not further increase the absolute ID (113 ± 4.6 μm, p<0.001) and normalized ID (41 ± 1.5%, p<0.001).
Figure 17: No differences in ACE mRNA expression were observed between *Myh11-4a12* and wild type mice in mesenteric arteries.

Wild Type: N=5; *Myh11-4a12*: N=8. Means ± SEM, student t-test.
Figure 18: Western blot analysis of eNOS and VASP phosphorylation in aorta.

A) Serine 1177 phospho-eNOS/β-tubulin and B) total eNOS/ β-tubulin. N=6 wild type – vehicle and Myh11-4a12 – vehicle; N=7 Myh11-4a12 – AAA, *p<0.05 one-way ANOVA. C) Serine 239 phospho-VASP/total VASP. N=5 wild type – vehicle N=4 Myh11-4a12 – vehicle and Myh11-4a12 – AAA, **p<0.01, One-way ANOVA.
Figure 19: Phosphorylation of eNOS at serine 1177 after 12 days of AAA treatment in mesenteric arteries of Myh11-4a12 mice.

Figure 20: Myh11-4a12 mice have elevated phosphorylation of myosin light chain that was reduced with 12 day AAA treatment.

A) Western blot analysis of Serine 19 phospho-myosin light chain expression in mesenteric arteries after 12-day AAA treatment (N=7 Wild Type – Vehicle and Myh11-4a12-vehicle; N=6 Myh11-4a12 - AAA, one-way ANOVA.
Figure 21: ROCK1 protein expression was elevated in Myh11-4a12 mice.

Wild type: N=5; Myh11-4a12: N=6, *p<0.05, student t-test.
Figure 22: Addition of AAA or Y-27632 prevented 20-HETE-mediated increase in myogenic tone of RIA from WT mice.

A) absolute internal diameter (ID) and B) percent myogenic tone. Vehicle, 20-HETE only, 20-HETE + AAA, 20-HETE + Y-27632 – N= 6 mice, n=12 vessels; 20-HETE + AAA + Y-27632 – N = 4 mice, n=8 vessels.
Figure 23: Absolute internal diameter (ID) and percent myogenic tone values of WT RIA at 80mmHg and 100mmHg.

A) absolute and B) normalized ID at 80 mmHg and C) absolute and D) normalized ID at 100 mmHg. Vehicle, 20-HETE only, 20-HETE + AAA, 20-HETE + Y-27632 – N = 6 mice, n=12 vessels; 20-HETE + AAA + Y-27632 – N = 4 mice, n=8 vessels. *p<0.05, **p<0.01, ***p<0.001 vs vehicle treated. ##p<0.01, ###p<0.001 vs 20-HETE treated one-way ANOVA.
Discussion

The present study provides evidence to show the actions of 20-HETE within the vascular smooth muscle cell to promote hypertension and vascular dysfunction. The main findings of this study include: 1) vascular smooth muscle-specific overexpression of Cyp4a12 and increased vascular production of 20-HETE was sufficient to promote increases in blood pressure and impairment in vascular function; 2) treatment with a novel, water-soluble 20-HETE receptor antagonist (AAA) reversed the pathology associated with 20-HETE overproduction; 3) elevated 20-HETE changes signaling within the VSMC and EC which was reversed with AAA treatment. The signaling mechanisms that were assessed were Rho-kinase-mediated myosin light chain phosphorylation and NO signaling.

The actions of 20-HETE within the vasculature have been extensively shown in animal models with global overproduction of 20-HETE. These models have consistently shown that increased 20-HETE within the vasculature promotes hypertension and vascular dysfunction. The limitation of using global models of 20-HETE production is the difficulty to dissect how 20-HETE within specific cell types contributes to changes in vascular function. The utilization of animal models with site-specific expression of 20-HETE can better show the mechanism in which 20-HETE produces changes in vascular function with a certain cell type.

In this study, the cre/flox system was utilized to target Cyp4a12 overexpression to the smooth muscle cell. The reason for this approach of
Cyp4a12 overexpression was to overproduce 20-HETE in the primary site of synthesis (Harder et al., 1994; Gebremedhin et al., 1998). 20-HETE has been shown to produce effects within the VSMC to change blood pressure and vascular function in vitro and in models of global overproduction of 20-HETE. This is the first time that Cyp4a12 was endogenously overexpressed in the VSMC to produce 20-HETE in a mouse.

The mouse model that was used in the present study was appropriate to assess the consequence of 20-HETE overproduction generated by the VSMC. The cre/lox system was used to target Cyp4a12 production, specifically in the VSMC. The Cyp4a12-flox gene was constructed to have the regulatory unit of the gene flanked with the LoxP site. In the presence of cre-recombinase, the regulatory unit of the gene was removed to allow for unregulated production of Cyp4a12 (Gilani et al., 2020). Cyp4a12-flox expression was targeted to the VSMC by site-specific cre-recombinase production under the control of the smooth muscle-specific myosin heavy chain promoter (Myh11-Cre) (Xin et al., 2002). This was evident when probing for Cyp4a12 expression at the mRNA and protein level. In mesenteric and RIAs, there was significant increase in Cyp4a12 mRNA expression compared to WT mice. There was also a significant increase in Cyp4a protein levels in the mesenteric artery compared to WT mice. These changes were not observed in the liver.

The result of the VSMC-specific overexpression of Cyp4a12 was elevated 20-HETE levels. Elevated 20-HETE levels were observed in mesenteric arteries, RIA, and plasma; however, no change in 20-HETE was observed in urine. This
gives evidence that 20-HETE production is directed to the vessels, but the 20-
HETE produced in the vessels can be found in circulating stores. Mice with
elevated 20-HETE also had elevated systolic blood pressure and impairments in
acetylcholine-induced relaxation. When performing western blots to reinforce the
results from the ex vivo experiments in vessels, changes in eNOS expression in
the aorta and serine 19 phospho-myosin light chain expression were also
observed. Altogether, the results demonstrate that VSMC-specific Cyp4a12
expression results in elevated 20-HETE and impairments in vascular activity,
which contribute to changes in systolic blood pressure.

Global overexpression models of 20-HETE are shown to cause increases
in blood pressure and impairment in vascular reactivity. One model of global
overproduction of 20-HETE is the Cyp4a14−/−-mouse. The Cyp4a14−/−-mouse has
global overexpression of Cyp4a12, the main 20-HETE-producing enzyme in
mice, and its expression is driven by the androgen promoter. This mouse model
resulted in elevated 20-HETE levels in male mice but not in female (Holla et al.,
2001). Increase in blood pressure and impairment in vascular reactivity are
associated with elevated 20-HETE in these mice. In a report by Pandey et. al.
(2017), they showed that Cyp4a14−/−-mice had increases in blood pressure and
changes in phenylephrine-induced contraction that were reversed with a 20-
HETE antagonist (Pandey et al., 2017).

Another model of constitutive 20-HETE overproduction was the Tie2-
CYP4F2-Tr mouse model. CYP4F2 is a major 20-HETE-producing enzyme in
humans with CYP4F2 activity associated with hypertension (Ward et al., 2008).
The investigators were interested in CYP4F2 expression within the vessels which may contribute to 20-HETE-dependent vascular pathology. In their report, they generated a mouse model that had CYP4F2 expression controlled by the EC-specific Tie-2 promoter (Cheng et al., 2014). These mice exhibit elevated CYP4F2 expression with corresponding 20-HETE elevation, specifically in the EC. There were no differences in blood pressure and acetylcholine-induced relaxation but there were differences in phenylephrine-induced contraction.

Furthermore, the investigators showed a pro-angiogenic phenotype in the Tie2-CYP4F2-Tr mouse. This suggests that EC-specific CYP4F2 expression primarily drives changes in angiogenesis and changes in vascular function may be secondary to the actions of 20-HETE in the EC.

Each mouse model has its utilities when studying the mechanism of vascular impairment dependent on 20-HETE. The Cyp4a14−/− mouse model is a good model for reliable, global 20-HETE overproduction (CC Wu et al., 2013; Ding et al., 2013; Pandey et al., 2017). It has been used to identify the ability of 20-HETE to impair vascular function (Ding et al., 2013; Pandey et al., 2017).

However, the limitation of using the Cyp4a14−/− mouse is its inability to identify 20-HETE’s action within specific tissue types to promote vascular impairments. The Tie2-CYP4F2-Tr is one model of 20-HETE overproduction within the EC. It has been documented that this mouse line was not able to produce any changes in blood pressure, but was able to promote a pro-angiogenic phenotype (Cheng et al., 2014). Thus, there are limitations of using the Tie2-CYP4F2-Tr mouse when it comes to assessing mechanisms of blood pressure. In the present study, the
*Myh11-4a12* mouse showed elevated 20-HETE levels in vessels which were associated with increases in blood pressure and impairments in vascular function. Thus, the different phenotypes observed with different mouse models of 20-HETE overproduction are influenced by the site of 20-HETE overproduction.

AAA was used to assess the dependence of 20-HETE on blood pressure, vascular reactivity and remodeling. In the present study, 12 days of AAA treatment was sufficient to lower blood pressure to a value similar to the wild type controls. Phenylephrine-induced contraction and acetylcholine-induced relaxation both were improved after 12 days of AAA treatment. *Ex vivo* experiments to assess AAA direct action on RIA showed that mice with *Cyp4a12* overexpression had improved relaxation compared to untreated mice, and no changes were observed in WT mice. Interestingly, when assessing vascular remodeling, only the media:lumen ratio was affected by AAA. Media thickness or cross-sectional area was unchanged after AAA treatment.

AAA has been documented as a 20-HETE receptor antagonist capable of lowering blood pressure in models of 20-HETE-dependent hypertension (Sedláková *et al.*, 2018). In a report by Sedláková *et al.* (2018), they used the *Cyp1a1-Ren-2* rat model that has overproduction of 20-HETE and angiotensin II (Sedláková *et al.*, 2018). The investigators administered AAA for 12 days in the drinking water and they showed a significant reduction in systolic blood pressure compared to untreated hypertensive rats. The reduction in systolic blood pressure was accompanied by improved renal function. The spontaneous hypertensive rat is another model of hypertension that is 20-HETE-dependent.
Two reports showed that AAA treatment in the spontaneous hypertensive rat lowers blood pressure and improves renal function. In one report, AAA was administered IV and reductions in mean arterial blood pressure were observed (Walkowska et al., 2021). The changes in mean arterial blood pressure were accompanied by improvements in renal blood flow. Another report using the spontaneous hypertensive rat administered AAA in the drinking water rather than IV. The authors reported reductions in systolic blood pressure after 36 days of AAA treatment, although the reduction was not significant compared to the hypertensive controls (Gawrys et al., 2020). The reduction in systolic blood pressure was accompanied by improvements in renal function as assessed by reductions in albuminuria.

Fluid balance and sodium excretion was measured to determine if the blood pressure lowering effect of AAA had a renal component. Previous reports suggest that AAA was able to improve renal parameters which contributed to the lowering of blood pressure (Sedlaková et al., 2018; Gawrys et al., 2020; Walkowska et al., 2021). The goal of this experiment was to examine if AAA can affect sodium excretion and fluid balance in Myh11-4a12 mice. The Myh11-4a12 mice displayed no differences in 20-HETE levels in the urine compared to WT mice. Urine volume and sodium excretion were similar between WT and Myh11-4a12 mice. AAA appeared to increase urine volume and sodium excretion in Myh11-4a12 mice compared to Myh11-4a12 mice on vehicle. Due to the similar values between WT and Myh11-4a12 mice and the small sample size, no conclusions were made surrounding AAA and its effects across the kidney.
20-HETE within the kidney display effects to promote changes in blood pressure through regulation of salt and fluid handling. *In vivo* experiments have demonstrated 20-HETE’s pro- and anti-hypertensive role in the kidney. In experiments that manipulate 20-HETE levels acutely, 20-HETE was shown to be antihypertensive. Elevated 20-HETE within the kidney inhibits Na+/K+-ATPase (Schwartzman *et al.*, 1985; Nowicki *et al.*, 1997), and NKCC2 (Amlal *et al.*, 1998; Ito and Roman, 1999). These actions facilitate the reduction of blood pressure through increased salt and fluid excretion. On the other hand, 20-HETE has been shown to elevate blood pressure through changes in renal blood flow and sodium reabsorption in animal models with 20-HETE-dependent hypertension. Animal models of 20-HETE-dependent hypertension include: 1) *Cyp4a14*−/− (Quigley *et al.*, 2009; Pandey *et al.*, 2017), 2) *Cyp4a11* transgenic mouse (Savas *et al.*, 2016), 3) proximal tubule targeted *Cyp4a12* (*PT-4a12*) mouse (Gilani *et al.*, 2020). The *Cyp4a14*−/− mouse display reductions in renal blood flow (Pandey *et al.*, 2017) and increase in activity of the sodium hydrogen exchanger (NHE3) (Quigley *et al.*, 2009), both which promote sodium and fluid retention. In both the *Cyp4a11* transgenic and *PT-4a12* mouse, 20-HETE has been shown to increase expression of serum- and glucocorticoid-inducible kinase-1 (SGK-1) and increase activity of the sodium chloride exchanger (NCC) to increase sodium and fluid reabsorption (Savas *et al.*, 2016; Gilani *et al.*, 2020).

The differences in the actions of 20-HETE on renal function may be due to the acute vs chronic manipulations of 20-HETE levels. In the experimental models to address the anti-hypertensive actions of 20-HETE, experiments were
done on wild type animals (Schwartzman et al., 1985; Nowicki et al., 1997; Amlal et al., 1998) or the Dahl salt-sensitive hypertensive rat (Ito and Roman, 1999). The changes in blood pressure have been induced either by exogenous administration of 20-HETE or pharmacological manipulations to endogenously increase 20-HETE. In mouse models with 20-HETE-dependent hypertension, 20-HETE is elevated in renal microvessels (CC Wu et al., 2013) or urine (Gilani et al., 2020). 20-HETE in these animal models are constitutively elevated and the prolonged 20-HETE exposure is associated with compensatory changes in renal blood flow and salt reabsorption resulting in hypertension.

The mechanism by which 20-HETE promotes smooth muscle cell contraction has been studied extensively. 20-HETE is able to inhibit the BKCa2+-channel to increase levels of intracellular calcium (Lauterbach et al., 2002; Garcia et al., 2017). This action has been shown to be dependent on 20-HETE binding to its receptor (GPR75) (Garcia et al., 2017). 20-HETE can increase activity of Rho-kinase promoting the sensitization of smooth muscle cells to contraction (Randriamboavonjy et al., 2003). However, there are no current reports to suggest that this action is mediated by the 20-HETE receptor.

Vascular smooth muscle cells have a unique property in which they can display one of two phenotypes. On one hand, they can exhibit a synthetic phenotype in which VSMC are capable of synthesizing proteins to induce migration and proliferation (D Stec et al., 2007; Orozco et al., 2013). On the other hand, VSMC can exhibit a contractile phenotype. The phenotype in which the VSMC is exhibiting can be shown through measurements of VSMC differentiation
markers. The markers used for the determination of the VSMC phenotype are: *Myh11*, *Tagln*, and *Acta2* (Frismaniene *et al.*, 2018). If the VSMC is exhibiting a synthetic phenotype, the expression of VSMC markers should be lower compared to controls. If the VSMC is exhibiting a contractile phenotype, the markers should be elevated compared to controls. The present study suggests that the *Myh11-4a12* mice vessels are in a contractile phenotype (Frismaniene *et al.*, 2018). Markers of VSMC differentiation were measured and mRNA levels of *Myh11*, *Tagln*, and *Acta2* were all elevated compared to wild type mice. The elevated markers of VSMC differentiation suggest that there are more cells that are capable of contraction.

To assess the cellular signaling involved in VSMC contraction, phosphorylation of myosin light chain (MLC) at serine 19 was performed. Phosphorylation of MLC is the downstream signaling event that needs to occur before excitation contraction coupling can occur in the VSMC (Driska *et al.*, 1981). Two reasons why MLC can remain phosphorylated include: 1) increase intracellular calcium promoting increase MLCK activity (Raina *et al.*, 2009) and/or 2) activation of ROCK signaling which inhibits myosin phosphatase and prevents the dephosphorylation of MLC (Noma *et al.*, 2012). In the current study, ROCK expression and activity were assessed because it has not been determined if 20-HETE-mediated changes in ROCK activity is receptor mediated.

*Myh11-4a12* mice had elevated phosphorylation levels compared to wild type and AAA treatment was able to reduce it. This suggests that myosin light chain phosphorylation is dependent on the 20-HETE receptor. ROCK1 protein
levels were measured and *Myh11-4a12* mice treated with either vehicle or AAA had elevated levels compared to wild type animals. This indicates that ROCK1 expression is not dependent on the 20-HETE receptor. If the 20-HETE receptor is not affecting ROCK expression, it may affect ROCK activity. *Ex vivo* experiments were performed in wild type mice to assess the mechanism in which 20-HETE increases myogenic tone. The current report shows that 20-HETE shifts the internal diameter curve downward, suggesting an increase in myogenic tone. Co-administration of 20-HETE plus AAA or Rho-kinase inhibitor (Y-27632) shift the internal diameter curve upward similar to control values. Finally, co-treatment of 20-HETE with AAA and Y-27632 had no further changes in myogenic tone. This suggests that Rho-kinase activity is acting downstream of the 20-HETE receptor to promote changes in the myogenic response.

The finding above is similar to that in the report by Randriamboavonjy *et al.* (2003). They determined that 20-HETE was capable of inducing contraction in small coronary arteries. Furthermore, they showed that small coronary arteries treated with 20-HETE had increased phosphorylation of MLC (Randriamboavonjy *et al.*, 2003). The 20-HETE-induced phosphorylation of MLC was prevented with Y-27632 treatment. The findings from Randriamboavonjy study and the results from the present study suggests 20-HETE, through its receptor, is capable of promoting Rho-kinase activity, and allows for MLC phosphorylation, promoting VSMC contraction.

Treatment of *Myh11-4a12* mice with AAA was unable to reverse the remodeling phenotype in these mice. Media thickness and cross-sectional area
remained elevated after 12 days of AAA therapy. In addition, Myh11 protein expression was also unaffected with AAA treatment. In this model of 20-HETE overexpression, VSMCs are in the contractile phenotype rather than the synthetic. This was shown when comparing expression to smooth muscle-specific differentiation markers. *Myh11-4a12* had elevated *Myh11, Tagln* and *Acta2* mRNA expression compared to wild types. If the VSMC were in a synthetic state, there should have been a reduction in the VSMC differentiation markers compared to WT mice (Frismantiene *et al.*, 2018). The mouse model used in this experiment was a constitutive overexpression of *Cyp4a12*. It is possible that the proliferative phenotype occurred early in development and then switched to a contractile phenotype once the mouse reached adulthood.

In other models of 20-HETE overexpression, the use of 20-HETE antagonists was able to prevent the remodeling phenotype (Ding *et al.*, 2013; Garcia, *et al.*, (2015b)). In these experimental models, 20-HETE was induced by DHT and was treated with a 20-HETE antagonist at the same time. Pharmacological antagonism of 20-HETE can prevent vascular remodeling in 20-HETE-dependent models; however, 20-HETE antagonism may not be able to reverse remodeling after it has been established. Further studies will have to be performed to understand the mechanisms in which 20-HETE induces VSMC proliferation.

Another finding in the present study was that *Myh11-4a12* mice had impairment in NO signaling. When assessing phosphorylation of eNOS at Serine 1177 in the aorta, *Myh11-4a12* mice had lower phosphorylated eNOS levels.
compared to wild type. The change in phosphorylated eNOS levels was attributed to a reduction in total eNOS expression in aorta. This observation was also shown in a rat model with endothelial specific Cyp4a2 overexpression (Inoue et al., 2009). The changes in phosphorylated eNOS expression in mesenteric arteries were attributed to changes in eNOS activity. Regardless, the reduction in eNOS phosphorylation will result in decreased NO bioavailability. The differences in changes in eNOS phosphorylation may be due to differences that can be observed in different vascular beds (Aird, 2007). Myh11-4a12 mice treated with AAA had elevated phosphorylated eNOS expression in both aorta and mesenteric arteries. Thus, changes in eNOS activation are due to 20-HETE acting through its receptor.

The changes in eNOS phosphorylation were also accompanied by changes in VASP phosphorylation. VASP is a protein within the smooth muscle that is activated by PKG. Activation of PKG requires NO from the EC to diffuse to the VSMC to activate soluble guanylyl cyclase and increase cGMP. Thus, it can be used as a marker for NO signaling occurring within the VSMC (Oelze et al., 2000). In aortas of Myh11-4a12 mice, there was a significant reduction of phosphorylated VASP compared to wild type. However, 12-day AAA therapy was not able to increase phosphorylated VASP in Myh11-4a12 mice. This result implies that other mechanisms may be present to reduce NO bioavailability that are unaffected by AAA treatment.

At baseline values, Myh11-4a12 had impaired acetylcholine-induced relaxation that was restored when vessels were treated with sodium nitroprusside
(NO donor). This gives evidence that *Myh11-4a12* mice have impairments in NO mediated vasodilation. One explanation that was shown in the present study was that eNOS activation was reduced. Another action that may have occurred is the increased production ROS. 20-HETE has been shown to increase ROS in both endothelium and VSMCs (Guo *et al.*, 2007; Lakhkar *et al.*, 2016). The generation of ROS can sequester NO away from the VSMC and prevent the activation of PKG.

Within the EC and VSMC, 20-HETE has been documented to display different mechanisms in ROS generation. 20-HETE was shown to increase NADPH oxidase activity in pulmonary EC (Medhora *et al.*, 2008); however, 20-HETE in human umbilical vein EC and human microvascular EC display NADPH oxidase-independent ROS generation (Guo *et al.*, 2007). 20-HETE was also shown to generate ROS in VSMC by promoting increased superoxide production by the mitochondria (Lakhkar *et al.*, 2016). The differences in cell-specific mechanism of ROS generation may explain why increases in eNOS phosphorylation after AAA was not accompanied by increased VASP phosphorylation. It is possible that AAA was not able to ameliorate all the ROS-generating effects of 20-HETE. Future studies will have to be performed in order to assess the mechanism of ROS generation in *Myh11-4a12* mice and whether AAA is capable of changing ROS amounts.

This study provides evidence that 20-HETE, through its receptor, is capable of increasing blood pressure and promoting changes in small artery vascular activity. One limitation of this study is that it cannot conclude that 20-
HETE is acting through GPR75 to promote smooth muscle contraction. There are no current reports showing direct binding of AAA to GPR75; however, work is being done to show that AAA binds to GPR75 (unpublished data). The relevance of GPR75 can be assessed by using siRNA capable of downregulating GPR75 expression. In the report by Garcia and colleagues (2017), they used siRNA to downregulate GPR75 expression in the vessels which promoted reductions in blood pressure and improvement in vascular reactivity. Furthermore, they showed that knock down of GPR75 reduced phosphorylation of the BK$_{Ca}^{2+}$-channel which inhibits the activity of the transporter (Garcia et al., 2017). Similar approaches can be used to assess the relevance of GPR75 on Rho-kinase activity. Furthermore, there are GPR75 global knockout and GPR75-flox mice that are available to further dissect the mechanisms in which GPR75 is involved.

A second limitation of this study was that the mouse model used was a constitutive overexpression of Cyp4a12. Due to this, it cannot be determined whether 20-HETE is causing increases in blood pressure that promotes vascular remodeling or if 20-HETE is causing remodeling followed by increases in blood pressure. In one report, the investigators suggest that remodeling in vessels is independent in changes of blood pressure. 20-HETE overproduction was induced by DHT treatment and, in order to mitigate the increase in blood pressure, reserpine was administered (Ding et al., 2013). Mice treated with both DHT and reserpine experienced vascular remodeling without increases in blood pressure. The utilization of an inducible model of Cyp4a12 expression in the VSMC may be able to show 20-HETE’s contribution on blood pressure and
vascular remodeling. There is a mouse line with cre-recombinase expression targeted in the VSMC that is inducible with tamoxifen treatment (Wirth et al., 2008). Similar experiments can be performed in which mice can be co-administered tamoxifen and AAA to determine if 20-HETE receptor antagonism can prevent remodeling in resistant vessels with Cyp4a12 overexpression. Furthermore, AAA can be administered after tamoxifen-induced Cyp4a12 expression to determine if 20-HETE receptor antagonism can reverse the remodeling phenotype (Gilani et al., 2018). From these treatment groups, more insight can be obtained with regards to 20-HETE receptor-mediated actions to alter VSMC remodeling.

Future experiments can be done to determine if AAA can reverse vascular remodeling. Twelve-day AAA treatment was not able to decrease RIA media thickness and cross-sectional area. One reason for AAA’s inability to reverse vascular remodeling is that the duration of treatment was too short to produce an effect. Vascular remodeling is a complex process that involves the production of new proteins to form a viable cell. These changes may take longer periods of time to produce a measurable effect. In addition, the VSMC that are present may take time to undergo apoptosis to reduce the number of cells within the vessel wall. There may be several mechanisms by which 20-HETE receptor antagonism can change signaling to inhibit VSMC proliferation.

Another explanation in which AAA was unable to reverse the vascular remodeling phenotype may be due to 20-HETE promoting hypertrophy in addition to or rather then proliferation. 20-HETE has been documented to
promote hypertrophy in cardiomyocytes that contributes to heart failure in experimental animals (El-Kadi and Zordoky, 2008; Zordoky et al., 2008). There are no reports to suggest that 20-HETE can contribute to hypertrophy in resistant vessels. It is possible that 20-HETE can promote hypertrophy due to its ability to increase ACE expression and activity followed by increased Ang II (Cheng et al., 2012; Garcia et al., 2016). Furthermore, 20-HETE has been documented to activate mitogenic signaling that can also contribute to VSMC hypertrophy (Uddin et al., 1998; Muthalif et al., 2001). Further experimentation can be performed to assess 20-HETE action to promote hypertrophy and to determine if AAA is able to prevent it.
**Perspective and Significance**

Hypertension is a global burden of which approximately one fourth of the world population is diagnosed. Hypertension is a risk factor for several diseases including myocardial infarction, stroke, and renal failure. Although therapies are present such as ACE inhibitors/ARBS, diuretics and beta-blockers to control blood pressure there is a percentage of the population that do not respond to these therapies. Thus, there is a need to identify novel mechanisms that can be probed to improve blood pressure.

20-HETE has been extensively studied and consistently shows its role in blood pressure regulation. Actions include: 1) endothelial dysfunction, 2) elevated sodium reuptake; 3) VSMC contraction and proliferation. The multifaceted actions of 20-HETE on blood pressure make it an ideal target for blood pressure control. The use of pharmacological tools to either reduce the synthesis or inhibit the action of 20-HETE have shown positive effects on blood pressure and vascular function. What was not known until recently was how 20-HETE was able to initiate its downstream effects in the cell. The work of Garcia and colleagues (2017) was the first report to identify GPR75 as the receptor for 20-HETE. Identification of a novel GPCR for 20-HETE make it an attractive target for pharmacological manipulations. Future studies will be performed to fully characterize the actions of 20-HETE on blood pressure and vascular function through GPR75.
References


